Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: December 2011


Abelson, J. L., Curtis, G. C., Sagher, O., et al. (2005). Deep brain stimulation for refractory obsessive-compulsive disorder. Biological Psychiatry, 57, 510–516.
Abler, B., Walter, H. and Erk, S. (2005). Neural correlates of frustration. Neuroreport, 16, 669–672.
Academy of Medical Sciences. (2008). Brain Science, Addiction and Drugs. London: Academy of Medical Sciences.
Addolorato, G., Leggio, L., Ferrulli, A., et al. (2007). Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet, 370, 1915–1922.
Adhikari, B., Kahende, J., Malarcher, A., et al. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. Morbidity and Mortality Weekly Report, 57, 1226–1228.
Adler, M. W. (1995). Human subject issues in drug-abuse research. Drug and Alcohol Dependence, 37, 167–175.
Agid, Y., Schupbach, M., Gargiulo, M., et al. (2006). Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?Journal of Neural Transmission. Supplementum, 70, 409–414.
Ahmed, S. H. (2010). Validation crisis in animal models of drug addiction: beyond non-disordered drug use toward drug addiction. Neuroscience & Biobehavioral Reviews, 35, 172–184.
AIHW. (2008). National Drug Strategy Household Survey: Detailed Findings. Canberra: Australian Institute of Health and Welfare.
Ainslie, G. (2000). A research-based theory of addictive motivation. Law and Philosophy: An International Journal for Jurisprudence and Legal Philosophy, 19, 77–115.
Ainslie, G. (2001). Breakdown of Will. New York: Cambridge University Press.
Akil, H., Brenner, S., Kandel, E., et al. (2010). Medicine. The future of psychiatric research: genomes and neural circuits. Science, 327, 1580–1581.
Alexander, B. K., Beyerstein, B. L., Hadaway, P. F., et al. (1981). Effect of early and later colony housing on oral ingestion of morphine in rats. Pharmacology, Biochemistry and Behavior, 15, 571–576.
Alexander, B. K., Coambs, R. B. and Hadaway, P. F. (1978). The effect of housing and gender on morphine self-administration in rats. Psychopharmacology, 58, 175–179.
Ali, R., Christie, P. and Lenton, S. (1999). The Social Impacts of the Cannabis Expiation Notice Scheme in South Australia. Summary Report Presented to the Ministerial Council on Drug Strategy. Canberra: Commonwealth Department of Health and Aged Care.
Alonso-Zaldivar, R. (2008). Senate passes genetic discrimination bill. Los Angeles Times. Available at: (Accessed 25 January, 2009.)
Alper, J. S. and Beckwith, J. (1993). Genetic fatalism and social-policy: the implications of behavior genetics research. Yale Journal of Biology and Medicine, 66, 511–524.
Amato, L., Davoli, M., Perucci, C. A., et al. (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment, 28, 321–329.
Ambermoon, P., Carter, A., Hall, W., et al. (2011). Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field. Addiction, 106, 283–293.
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders – Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
Anand, S. and Hotson, J. (2002). Transcranial magnetic stimulation: neurophysiological applications and safety. Brain and Cognition, 50, 366–386.
ANCD. (2005). Key Principles for the Reporting of Drug Issues. Canberra: Australian National Council on Drugs.
ANCD. (2007). The Australian Alcohol and Other Drugs Charter. Canberra: Australian National Council on Drugs.
Anderer, S. J. (1992). Introduction to the symposium: integrating legal and psychological perspectives on the right to personal autonomy. Villanova Law Review, 37, 1536–1568.
Anderlik, M. R. and Rothstein, M. A. (2001). Privacy and confidentiality of genetic information: what rules for the new science?Annual Review of Genomics and Human Genetics, 2, 401–433.
Andlin-Sobocki, P. and Rehm, J. (2005). Cost of addiction in Europe. European Journal of Neurology, 12 Suppl 1, 28–33.
Angermeyer, M. C. and Matschinger, H. (2005). Have there been any changes in the public's attitudes towards psychiatric treatment? Results from representative population surveys in Germany in the years 1990 and 2001. Acta Psychiatrica Scandinavica, 111, 68–73.
Anon. (2005). How volunteering for an MRI scan changed my life. Nature, 434, 17.
Anthony, J. C., Warner, L. and Kessler, R. C. (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology, 2, 244–268.
Anton, R. F., Oroszi, G., O'Malley, S., et al. (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry, 65, 135–144.
Aos, S., Miller, M., Drake, E., et al. (2006). Evidence-Based Public Policy Options to Reduce Future Prison Construction, Criminal Justice Costs, and Crime Rates. Olympia, WA: Washington State Institute for Public Policy.
Appelbaum, P. S. (2010). Law and psychiatry: genetic discrimination in mental disorders: the impact of the genetic information nondiscrimination act. Psychiatric Services, 61, 338–340.
Appelbaum, P. S., Roth, L. H., Lidz, C. W., et al. (1987). False hopes and best data: consent to research and the therapeutic misconception. Hastings Center Report, 17, 20–24.
Ardouin, C., Voon, V., Worbe, Y., et al. (2006). Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Movement Disorders, 21, 1941–1946.
Aronowitz, D. (1967). Civil commitment of narcotics addicts. Columbia Law Review, 67, 405–429.
Ascher, J. A., Cole, J. O. and Colin, J. N. (1995). Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry, 56, 395–401.
Ashcroft, R. (2005). Making sense of dignity. Journal of Medical Ethics, 31, 679–682.
Ashcroft, R., Campbell, A. and Capps, B. (2007). Ethical aspects of developments in neuroscience and drug addiction. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 439–466). London: Academic Press.
Ashcroft, R. and Franey, C. (2004). Further ethical and social issues in using a cocaine vaccine: response to Hall and Carter. Journal of Medical Ethics, 30, 341–343.
Audrain, J., Boyd, N. R., Roth, J., et al. (1997). Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. Addictive Behaviors, 22, 741–751.
Australian Press Council. (2001). Reporting guidelines: drugs and drug addiction. General Press Release No. 246. Available at: (Accessed 6 July 2009.)
Avery, L. and Campbell, S. (1941). Shock therapy as an aid to the withdrawal of morphine in addiction. Disorders of the Nervous System, 2, 333–335.
Babor, T., Caetano, R., Casswell, S., et al. (2003). Alcohol: No Ordinary Commodity. Research and Public Policy. Oxford: Oxford University Press.
Babor, T., Miller, P. and Edwards, G. (2010). Vested interests, addiction research and public policy. Addiction, 105, 4–5.
Backlar, P. (1996). Genes and behavior: will genetic information change the way we see ourselves?Community Mental Health Journal, 32, 205–209.
Badenoch, J. (2002). A death following ultra-rapid opiate detoxification: the General Medical Council adjudicates on a commercialized detoxification. Addiction, 97, 475–477.
Balasubramaniam, V., Kanaka, T. S. and Ramanujam, P. B. (1973). Stereotaxic cingulumotomy for drug addiction. Neurology India, 21, 63–66.
Baldwin, R. (1979). Proposals for the Drug and Alcohol Court Assessment Programme. Sydney: NSW Drug and Alcohol Authority Internal Paper.
Baler, R. D. and Volkow, N. D. (2006). Drug addiction: the neurobiology of disrupted self-control. Trends in Molecular Medicine, 12, 559–566.
Balfour, D. J. (2004). The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus accumbens [corrected]. Nicotine and Tobacco Research, 6, 899–912.
Ball, A. L. (2007). HIV, injecting drug use and harm reduction: a public health response. Addiction, 102, 684–690.
Ball, D. (2008). Addiction science and its genetics. Addiction, 103, 360–367.
Ball, D. and Collier, D. (2002). Substance misuse. In P. McGuffin, M. J. Owen and I. I. Gottesman (Eds.), Psychiatric Genetics and Genomics (pp. 267–302). Oxford: Oxford University Press.
Ball, D., Pembrey, M. and Stevens, D. (2007). Genomics. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 89–132). London: Academic Press.
Ballard, P. and Radley, A. (2009). Give it up for baby: a smoking cessation intervention for pregnant women in Scotland. Cases in Public Health Communication & Marketing, 3, 147–160.
Ballon, B. C. and Skinner, W. (2008). Attitude is a little thing that makes a big difference: reflection techniques for addiction psychiatry training. Academic Psychiatry, 32, 218–224.
Baltuch, G. H. and Stern, M. B. (2007). Deep Brain Stimulation for Parkinson's Disease. New York: Informa Healthcare.
Barclay, G. A. (1964). The Keeley League. Journal of the Illinois State Historical Society (1908–1984), 57, 341–365.
Barnes, R. E. (2000). Reefer madness: legal and moral issues surrounding the medical prescription of marijuana. Bioethics, 14, 16–41.
Barrett, D. and Nowak, M. (2009). The United Nations and drug policy: towards a human rights-based approach. In A. Constantinides and N. Zaikos (Eds.), The Diversity of International Law: Essays in Honour of Professor Kalliopi K. Koufa (pp. 449–477). Boston: Martinus Nijhoff Publishers.
Baudelaire, C. (2002). On Wine and Hashish. London: Hesperus.
Bauer, R., Pohl, S., Klosterkotter, J., et al. (2008). [Deep brain stimulation in the context of addiction – a literature-based systematic evaluation]. Fortschritte der Neurologie-Psychiatrie, 76, 396–401.
Baumeister, R. F. (2003). Ego depletion and self-regulation failure: a resource model of self-control. Alcoholism, Clinical and Experimental Research, 27, 281–284.
BBC News. (2004). ‘DNA test’ to help smokers quit. BBC News. Available at: (Accessed 25 January 2007.)
BBC News. (2007). Brain's ‘addiction centre’ found. BBC News. Available at: (Accessed 2 August 2007.)
Beauchamp, T. L. and Childress, J. F. (2001). Principles of Biomedical Ethics. New York: Oxford University Press.
Bechara, A. (2001). Neurobiology of decision-making: risk and reward. Seminars in Clinical Neuropsychiatry, 6, 205–216.
Bechara, A. (2005). Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nature Neuroscience, 8, 1458–1463.
Bechara, A., Dolan, S., Denburg, N., et al. (2001). Decision-making deficits, linked to a dysfunctional ventromedial prefrontal cortex, revealed in alcohol and stimulant abusers. Neuropsychologia, 39, 376–389.
Becker, A., Grecksch, G., Brodemann, R., et al. (2000). Morphine self-administration in mu-opioid receptor-deficient mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 361, 584–589.
Begg, S., Vos, T., Barker, B., et al. (2007). The Burden of Disease and Injury in Australia 2003. Canberra: Australian Institute of Health and Welfare.
Belenko, S. (2002). The challenges of conducting research in drug treatment court settings. Substance Use & Misuse, 37, 1635–1664.
Bell, E., Maxwell, B., Sadikot, A., et al. (2010). Healthcare providers' perspectives and approaches. Journal of Clinical Ethics, 21, 113–125.
Bell, J., Chan, J. and Kuk, A. (1995). Investigating the effect of treatment philosophy on outcome of methadone maintenance. Addiction, 90, 823–830.
Bell, J., Hall, W. and Byth, K. (1992). Changes in criminal activity after entering methadone maintenance. British Journal of Addiction, 87, 251–258.
Benabid, A. L., Pollak, P., Seigneuret, E., et al. (1993). Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurgica. Supplementum, 58, 39–44.
Bennett, P. and Smith, S. (2007). Genetics, insurance and participation: how a citizen's jury reached its verdict. Social Science and Medicine, 64, 2487–2498.
Bentham, J. (1988). The Principles of Morals and Legislation. Buffalo, NY: Prometheus Books.
Berke, J. D. (2003). Learning and memory mechanisms involved in compulsive drug use and relapse. Methods in Molecular Medicine, 79, 75–101.
Berke, J. D. and Hyman, S. E. (2000). Addiction, dopamine, and the molecular mechanisms of memory. Neuron, 25, 515–532.
Berridge, K. C. (2007). The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology, 191, 391–431.
Berridge, K. C. and Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?Brain Research Reviews, 28, 309–369.
Bersoff, D. N. (1992). Autonomy for vulnerable populations: the Supreme Court's reckless disregard for self-determination and social science. Villanova Law Review, 37, 1569–1605.
Bigelow, G. E., Brooner, R., Walsh, S., et al. (1994). Community outcomes following research exposure to cocaine or opioids. In: L. Harris. (Ed), Problems of Drug Dependence: Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence (Volume 2), 354. Baltimore, MD: National Institute on Drug Abuse.
Billings, P. R., Kohn, M. A., Decuevas, M., et al. (1992). Discrimination as a consequence of genetic testing. American Journal of Human Genetics, 50, 476–482.
Bjorklund, A. and Dunnett, S. B. (2007). Fifty years of dopamine research. Trends in Neurosciences, 30, 185–187.
Blakemore, C. (2002). From the “public understanding of science” to scientists' understanding of the public. In S. J. Marcus (Ed.), Neuroethics: Mapping the Field (pp. 211–221). New York: Dana Press.
Boeijinga, P. H., Parot, P., Soufflet, L., et al. (2004). Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology, 50, 71–77.
Bonese, K. F., Wainer, B. H., Fitch, F. W., et al. (1974). Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature, 252, 708–710.
Bonson, K. R., Grant, S. J., Contoreggi, C. S., et al. (2002). Neural systems and cue-induced cocaine craving. Neuropsychopharmacology, 26, 376–386.
Brandt, A. M. (2007). The Cigarette Century. Atlanta, GA: Basic Books.
Brebner, K., Ahn, S. and Phillips, A. G. (2005). Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates. Psychopharmacology, 177, 409–417.
Brodie, J. D., Figueroa, E., Laska, E. M., et al. (2005). Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse, 55, 122–125.
Brody, B. A. (1998). The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press.
Brody, B. A. (2003). Taking Issue: Pluralism and Casuistry in Bioethics. Washington, DC: Georgetown University Press.
Brown, S. M., Manuck, S. B., Flory, J. D., et al. (2006). Neural basis of individual differences in impulsivity: contributions of corticolimbic circuits for behavioral arousal and control. Emotion, 6, 239–245.
Bruce, R. D. and Schleifer, R. A. (2008). Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. International Journal of Drug Policy, 19, 17–23.
Bruijnzeel, A. W. and Gold, M. S. (2005). The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Research. Brain Research Reviews, 49, 505–528.
Bush, G., Whalen, P. J., Rosen, B. R., et al. (1998). The Counting Stroop: an interference task specialized for functional neuroimaging – validation study with functional MRI. Human Brain Mapping, 6, 270–282.
Cairns, R., Maddock, C., Buchanan, A., et al. (2005). Reliability of mental capacity assessments in psychiatric in-patients. British Journal of Psychiatry, 187, 372–378.
Calabresi, P., Picconi, B., Tozzi, A., et al. (2007). Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends in Neurosciences, 30, 211–219.
Callahan, D. (2003). Principlism and communitarianism. Journal of Medical Ethics, 29, 287–291.
Campbell, D. E. and Fleischman, A. R. (1992). Ethical challenges in medical care for the pregnant substance abuser. Clinical Obstetrics and Gynecology, 35, 803–812.
Campbell, N. C. (2007). Discovering Addiction: The Science and Politics of Substance Abuse Research. Ann Arbor: University of Michigan Press.
Canli, T. and Amin, Z. (2002). Neuroimaging of emotion and personality: scientific evidence and ethical considerations. Brain and Cognition, 50, 414–431.
Cantin, L., Lenoir, M., Augier, E., et al. (2010). Cocaine is low on the value ladder of rats: possible evidence for resilience to addiction. PLoS ONE, 5, e11592.
Caplan, A. (2002). No brainer: can we cope with the ethical ramifications of new knowledge of the human brain. In S. Marcus (Ed.), Neuroethics: Mapping the Field (pp. 95–131). San Francisco: The Dana Press.
Caplan, A. (2006). Ethical issues surrounding forced, mandated, or coerced treatment. Journal of Substance Abuse Treatment, 31, 117–120.
Caplan, A. (2008). Denying autonomy in order to create it: the paradox of forcing treatment upon addicts. Addiction, 103, 1919–1921.
Caplan, A. and Elliott, C. (2004). Is it ethical to use enhancement technologies to make us better than well?PLoS Medicine, 1, e52.
Cappella, J. N., Lerman, C., Romantan, A., et al. (2005). News about genetics and smoking. Communication Research, 32, 478.
Capps, B. (2007). Authoritative regulation and the stem cell debate. Bioethics Quarterly, 22, 43–55.
Capps, B., Campbell, A. V. and ter Meulen, R. (2008). Access to the UK Biobank Resource: Concepts of the Public Interest and the Public Good. London: Ethics and Governance Council of UK Biobank and the Wellcome Trust.
Carlsten, C. and Burke, W. (2006). Potential for genetics to promote public health: genetics research on smoking suggests caution about expectations. Journal of the American Medical Association, 296, 2480–2482.
Caron, L., Karkazis, K., Raffin, T. A., et al. (2005). Nicotine addiction through a neurogenomic prism: ethics, public health, and smoking. Nicotine & Tobacco Research, 7, 181–197.
Carpenter, M. J., Strange, C., Jones, Y., et al. (2007). Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Annals of Behavioral Medicine, 33, 22–28.
Carter, A., Ambermoon, P. and Hall, W. (2010a). Drug-induced impulse control disorders: a prospectus for neuroethical analysis. Neuroethics, DOI: 10.1007/s12152–010–9071–7.
Carter, A., Bell, E., Racine, E., et al. (2010b). Ethical issues raised by proposals to treat addiction using deep brain stimulation. Neuroethics, 1–14.
Carter, A., Capps, B. and Hall, W. (2009). Addiction Neurobiology: Ethical and Social Implications. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
Carter, A. and Hall, W. (2007a). The Ethical Use of Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization.
Carter, A. and Hall, W. (2007b). The social implications of neurobiological explanations of resistible compulsions. American Journal of Bioethics, 7, 15–17.
Carter, A. and Hall, W. (2008a). Informed consent to opioid agonist maintenance treatment: recommended ethical guidelines. International Journal of Drug Policy, 19, 79–89.
Carter, A. and Hall, W. (2008b). The issue of consent in research that administers drugs of addiction to addicted persons. Accountability in Research, 15, 209–225.
Carter, A. and Hall, W. (2011). Proposals to trial deep brain stimulation to treat addiction are premature. Addiction, 106, 235–237.
Casebeer, W. D. (2003). Natural Ethical Facts: Evolution, Connectionism, and Moral Cognition. Cambridge, MA: MIT Press.
Caspi, A. and Moffitt, T. E. (2006). Gene–environment interactions in psychiatry: joining forces with neuroscience. Nature Reviews. Neuroscience, 7, 583–590.
Cerny, E. H. and Cerny, T. (2008). Anti-nicotine abuse vaccines in the pipeline: an update. Expert Opinion on Investigational Drugs, 17, 691–696.
Chambers, R. A. (2008). Impulsivity, dual diagnosis, and the structure of motivated behavior in addiction. Behavioral and Brain Sciences, 31, 443–444.
Chandler, R. K., Fletcher, B. W. and Volkow, N. D. (2009). Treating drug abuse and addiction in the criminal justice system: improving public health and safety. JAMA, 301, 183–190.
Chapman, S. and MacKenzie, R. (2010). The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Medicine, 7, e1000216.
Charland, L. C. (2002). Cynthia's dilemma: consenting to heroin prescription. American Journal of Bioethics, 2, 37–47.
Chatterjee, A. (2004). Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology, 63, 968–974.
Chatterjee, A. (2006). The promise and predicament of cosmetic neurology. Journal of Medical Ethics, 32, 110–113.
Chatterjee, A. (2007). Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Cambridge Quarterly of Healthcare Ethics, 16, 129–137.
Chavkin, W. (1996). Mandatory treatment for pregnant substance abusers: irrelevant and dangerous. Politics and the Life Sciences, 15, 53–54.
Chen, Y. C., Lu, R. B., Peng, G. S., et al. (1999). Alcohol metabolism and cardiovascular response in an alcoholic patient homozygous for the ALDH2*2 variant gene allele. Alcoholism, Clinical and Experimental Research, 23, 1853–1860.
Chervenak, F. A. and McCullough, L. B. (1997). Ethics in obstetrics and gynecology: an overview. European Journal of Obstetrics and Gynecology, 75, 91–94.
Childress, A. R., Mozley, P. D., McElgin, W., et al. (1999). Limbic activation during cue-induced cocaine craving. American Journal of Psychiatry, 156, 11–18.
Childress, J. F., Faden, R. R., Gaare, R. D., et al. (2002). Public health ethics: mapping the terrain. Journal of Law Medicine & Ethics, 30, 170–178.
Christensen, R., Kristensen, P. K., Bartels, E. M., et al. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet, 370, 1706–1713.
Chuck, A., Jacobs, P., Logus, J. W., et al. (2005). Marginal cost of operating a positron emission tomography center in a regulatory environment. International Journal of Technology Assessment in Health Care, 21, 442–451.
Churchland, P. S. (1986). Neurophilosophy: Toward a Unified Science of the Mind-brain. Cambridge, MA.: MIT Press.
Clancey, G. and Howard, J. (2006). Diversion and criminal justice drug treatment: mechanism of emancipation or social control?Drug and Alcohol Review, 25, 377–385.
Cohen, J. (2004). HIV/AIDS in China. Changing course to break the HIV–heroin connection. Science, 304, 1434–1435.
Cohen, J. and Csete, J. (2006). As strong as the weakest pillar: harm reduction, law enforcement and human rights. International Journal of Drug Policy, 17, 101–103.
Cohen, J. E. and Amon, J. J. (2008). Health and human rights: concerns of drug users in detention in Guangxi Province, China. PLoS Medicine, 5, e234.
Cohen, P. J. (1997). Immunization for prevention and treatment of cocaine abuse: legal and ethical implications. Drug and Alcohol Dependence, 48, 167–174.
Cohen, P. J. (2002). Untreated addiction imposes an ethical bar to recruiting addicts for non-therapeutic studies of addictive drugs. Journal of Law, Medicine & Ethics, 30, 73–81.
Cohen, R. S. (1998). The Love Drug: Marching to the Beat of Ecstasy. New York: Haworth Medical Press.
Collins, D. and Lapsley, H. (2007). The Avoidable Costs of Alcohol Abuse in Australia and the Potential Benefits of Effective Policies to Reduce the Social Costs of Alcohol. Canberra: Department of Health and Ageing, Commonwealth of Australia.
Collins, D. and Lapsley, H. (2008). The Costs of Tobacco, Alcohol and Illicit Drug Use to Australian Society in 2004/05. National Drug Strategy Monograph No. 64. Canberra: Department of Health and Ageing, Commonwealth of Australia.
Collins, F. (1999). Medical and societal consequences of the Human Genome Project. New England Journal of Medicine, 341, 28–37.
Collins, F. (2003). A vision for the future of genomics research. Nature, 433, 835–847.
Comer, S. D., Sullivan, M. A., Yu, E., et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Archives of General Psychiatry, 63, 210–218.
Condit, C., Parrott, R. and Harris, T. (2006). Laypeople and behavioural genetics. In E. Parens, A. R. Chapman and N. Press (Eds.), Wrestling with Behavioral Genetics: Science, Ethics and Public Conversation (pp. 286–308). Baltimore, MD: Johns Hopkins University Press.
Conrad, P. (1992). Medicalization and social control. Annual Review of Sociology, 18, 209–232.
Contreras, M., Ceric, F. and Torrealba, F. (2007). Inactivation of the interoceptive insula disrupts drug craving and malaise induced by lithium. Science, 318, 655–658.
Cook, P. J. (2007). Paying the Tab: The Economics of Alcohol Policy. Princeton, NJ: Princeton University Press.
Cornuz, J., Zwahlen, S., Jungi, W. F., et al. (2008). A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS ONE, 3, e2547.
Cosgrove, K. P. (2010). Imaging receptor changes in human drug abusers. In D.W. Self and J.K.Staley Gottschalk (Eds.), Behavioral Neuroscience of Drug Addiction (Vol. 3, pp. 199–217). Berlin: Springer.
Courtwright, D. T. (1982). Dark Paradise: Opiate Addiction in America Before 1940. Cambridge, MA: Harvard University Press.
Courtwright, D. T. (2001). Forces of Habit: Drugs and the Making of the Modern World. Cambridge, MA: Harvard University Press.
Cousins, M. S., Roberts, D. C. and de Wit, H. (2002). GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug and Alcohol Dependence, 65, 209–220.
Cox, W. M., Hogan, L. M., Kristian, M. R., et al. (2002). Alcohol attentional bias as a predictor of alcohol abusers' treatment outcome. Drug and Alcohol Dependence, 68, 237–243.
Craig, A. D. (2002). How do you feel? Interoception: the sense of the physiological condition of the body. Nature Reviews. Neuroscience, 3, 655–666.
Crick, F. (1995). The Astonishing Hypothesis: The Scientific Search for the Soul. New York: Simon & Schuster.
Cunningham, M. G., Bhattacharyya, S. and Benes, F. M. (2002). Amygdalo-cortical sprouting continues into early adulthood: implications for the development of normal and abnormal function during adolescence. Journal of Comparative Neurology, 453, 116–130.
Curran, H. V. (1991). Benzodiazepines, memory and mood: a review. Psychopharmacology, 105, 1–8.
Curran, H. V., Kleckham, J., Bearn, J., et al. (2001). Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology, 154, 153–160.
Dackis, C., Kampman, K., Lynch, K., et al. (2004). A double-blind, placebo-controlled trial of modafinil in cocaine dependence. Neuropsychopharmacology, 29, S72–S73.
Dackis, C. and O'Brien, C. (2005). Neurobiology of addiction: treatment and public policy ramifications. Nature Neuroscience, 8, 1431–1436.
Daglish, M. R., Weinstein, A., Malizia, A. L., et al. (2001). Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. American Journal of Psychiatry, 158, 1680–1686.
Daglish, M. R., Williams, T. M., Wilson, S., et al. (2008). Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 193, 65–72.
Dalrymple, T. (2006). Romancing Opiates: Pharmacological Lies and the Addiction Bureaucracy. New York: Encounter Books.
Damasio, A. R. (1999). The Feeling of What Happens: Body and Emotion in the Making of Consciousness. New York: Harcourt Brace.
Damasio, A. R., Grabowski, T. J., Bechara, A., et al. (2000). Subcortical and cortical brain activity during the feeling of self-generated emotions. Nature Neuroscience, 3, 1049–1056.
Daniel, M., Martin, A. D. and Carter, J. (1992). Opiate receptor blockade by naltrexone and mood state after acute physical activity. British Journal of Sports Medicine, 26, 111–115.
Darke, S. and Hall, W. (2003). Heroin overdose: research and evidence-based intervention. Journal of Urban Health, 80, 189–200.
Darke, S. and Ross, J. (2002). Suicide among heroin users: rates, risk factors and methods. Addiction, 97, 1383–1394.
Darke, S. and Zador, D. (1996). Fatal heroin ‘overdose’: a review. Addiction, 91, 1765–1772.
Davies, J. B. (1997). The Myth of Addiction. Amsterdam: Harwood Academic.
De Quincey, T. (1900). Confessions of an Opium Eater. Literary Reminiscences. New York: D. Appleton.
Dean, A. J., Saunders, J. B., Jones, R. T., et al. (2006). Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. Journal of Psychiatry and Neuroscience, 31, 38–45.
Degenhardt, L., Bucello, C., Mathers, B., et al. (2011). Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction, 106, 32–51.
Demyttenaere, K., Bruffaerts, R., Posada-Villa, J., et al. (2004). Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. Journal of the American Medical Association, 291, 2581–2590.
Devlin, M. J. (2007). Is there a place for obesity in DSM-V?International Journal of Eating Disorders, 40 Suppl, S83–88.
Dewey, J. (1990). Logic: The Theory of Inquiry. Carbondale: Southern Illinois University Press.
Di Chiara, G. (1998). A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. Journal of Psychopharmacology, 12, 54–67.
Dieckmann, G. and Schneider, H. (1978). Influence of stereotactic hypothalamotomy on alcohol and drug addiction. Applied Neurophysiology, 41, 93–98.
Diefenbach, G. J., Diefenbach, D., Baumeister, A., et al. (1999). Portrayal of lobotomy in the popular press: 1935–1960. Journal for the History of the Neurosciences, 8, 60–69.
Dietrich, S., Matschinger, H. and Angermeyer, M. (2006). The relationship between biogenetic causal explanations and social distance toward people with mental disorders: results from a population survey in Germany. International Journal of Social Psychiatry, 52, 166–174.
Digiusto, E., Shakeshaft, A., Ritter, A., et al. (2004). Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction, 99, 450–460.
Dolan, K. (1999). The Epidemiology of Hepatitis C Infection in Prison Populations. Sydney: National Drug and Alcohol Research Centre, UNSW.
Dolan, K., Kite, B., Black, E., et al. (2006). HIV in prison in low-income and middle-income countries. The Lancet Infectious Diseases, 7, 32–41.
Dolan, K., Wodak, A., Hall, W., et al. (1996). HIV risk behaviour of injecting drug users before, during and after imprisonment in New South Wales. Addictive Research, 4, 151–160.
Dole, V. P. and Nyswander, M. (1965). A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. Journal of the American Medical Association, 193, 646.
Domes, G., Heinrichs, M., Glascher, J., et al. (2007a). Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry, 62, 1187–1190.
Domes, G., Heinrichs, M., Michel, A., et al. (2007b). Oxytocin improves “mind-reading” in humans. Biological Psychiatry, 61, 731–733.
Donnelly, N., Hall, W. and Christie, P. (1995). The effects of partial decriminalisation on cannabis use in South Australia, 1985 to 1993. Australian Journal of Public Health, 19, 281–287.
Doran, C. M., Hall, W., Shakeshaft, A. P., et al. (2010). Alcohol policy reform in Australia: what can we learn from the evidence?The Medical Journal of Australia, 192, 468.
Doyle, C. (2004). DNA test can identify ‘the smoker's gene’. The Telegraph. Available at: (Accessed 25 January 2007.)
Drevets, W. C., Gautier, C., Price, J. C., et al. (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry, 49, 81–96.
Dumit, J. (2004). Picturing Personhood: Brain Scans and Biomedical Identity. Princeton, NJ: Princeton University Press.
Dunn, L. B. and Jeste, D. V. (2001). Enhancing informed consent for research and treatment. Neuropsychopharmacology, 24, 595–607.
Dunn, L. B., Nowrangi, M. A., Palmer, B. W., et al. (2006). Assessing decisional capacity for clinical research or treatment: a review of instruments. American Journal of Psychiatry, 163, 1323–1334.
Dworkin, G. (1972). Paternalism. Monist, 56, 64–84.
Ebbets, J. (1994). Applicability of the CIWA-A scale. Clinical Institute Withdrawal Assessment for Alcohol. Journal of Nursing Care Quality, 8, ix–x.
Economic and Social Research Council. (2005). Research Ethics Framework (REF). Swindon, UK: Economic and Social Research Council.
Eigsti, I. M., Zayas, V., Mischel, W., et al. (2006). Predicting cognitive control from preschool to late adolescence and young adulthood. Psychological Science, 17, 478–484.
Elliott, C. (2002). Who holds the leash?American Journal of Bioethics, 2, 48.
Elliott, C. (2003). Better Than Well: American Medicine Meets the American Dream. New York: W.W. Norton.
Elliott, R., Csete, J., Wood, E., et al. (2005). Harm reduction, HIV/AIDS, and the human rights challenge to global drug control policy. Health and Human Rights, 8, 104–138.
Elster, J. and Skog, O. -J. (1999). Getting Hooked: Rationality and Addiction. Cambridge, UK: Cambridge University Press.
EMCDDA. (2006). Annual Report on the State of the Drugs Problem in the European Union, 2006. Belgium: European Monitoring Centre for Drugs and Drug Addiction.
Epstein, D. H., Preston, K. L., Stewart, J., et al. (2006). Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology, 189, 1–16.
Ersche, K., Fletcher, P. C., Lewis, S. J., et al. (2005). Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology, 180, 612–623.
Ersche, K., Roiser, J., Lucas, M., et al. (2011). Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment. Psychopharmacology, 214, 779–789.
Eskapa, R. D. (2008). The Cure for Alcoholism: Drink Your Way Sober Without Willpower, Abstinence, or Discomfort. The Sinclair Method, a Medically Proven Cure for Alcoholism. Dallas, TX: BenBella Books.
Evans, J. P., Meslin, E. M., Marteau, T. M., et al. (2011). Deflating the genomic bubble. Science, 331, 861–862.
Everitt, B. J. and Robbins, T. W. (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nature Neuroscience, 8, 1481–1489.
Ezzati, M., Lopez, A., Rogers, A., et al. (2004). Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization.
Faden, R. R., Beauchamp, T. L. and King, N. M. (1986). A History and Theory of Informed Consent. New York: Oxford University Press.
Faillace, L., Flamer, R., Imber, S., et al. (1972). Giving alcohol to alcoholics. Quarterly Journal of Studies on Alcohol, 33, 85–90.
Farabee, D. and Leukefeld, C. G. (2001). Recovery and the criminal justice system. In M. T. Frank, C. G. Leukefeld and J. J. Platt (Eds.), Relapse and Recovery in Addiction (pp. 40–59). London: Yale University Press.
Farah, M. J. (2002). Emerging ethical issues in neuroscience. Nature Neuroscience, 5, 1123–1129.
Farah, M. J. (2005). Neuroethics: the practical and the philosophical. Trends in Cognitive Sciences, 9, 34–40.
Farah, M. J. (2010). Neuroethics: An Introduction with Readings. Cambridge, MA: MIT Press.
Farah, M. J., Illes, J., Cook-Deegan, R., et al. (2004). Neurocognitive enhancement: what can we do and what should we do?Nature Reviews. Neuroscience, 5, 421–425.
Farah, M. J. and Wolpe, P. R. (2004). Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Center Report, 34, 35–45.
FDA. (2009). FDA approves humanitarian device exemption for deep brain stimulator for severe obsessive-compulsive disorder. Available at: (Accessed 31 August, 2009.)
FDA. (2010). FDA approves injectable drug to treat opioid-dependent patients. Available at: (Accessed 12 October, 2010.)
Featherby, T., van den Buuse, M., Lubman, D. I., et al. (2008). Persistent downregulation of hippocampal CREB mRNA parallels a Y-maze deficit in adolescent rats following semi-chronic amphetamine administration. British Journal of Pharmacology, 154, 417–428.
Fehr, C., Yakushev, I., Hohmann, N., et al. (2008). Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. American Journal of Psychiatry, 165, 507–514.
Feil, J., Sheppard, D., Fitzgerald, P. B., et al. (2010). Addiction, compulsive drug seeking, and the role of frontostriatal mechanisms in regulating inhibitory control. Neuroscience & Biobehavioral Reviews, 35, 248–275.
Feinberg, J. (1971). Legal paternalism. Canadian Journal of Philosophy, 1, 105–124.
Feinberg, J. (1980). Rights, Justice, and the Bounds of Liberty: Essays in Social Philosophy. Princeton, N.J.: Princeton University Press.
Feltenstein, M. W. and See, R. E. (2008). The neurocircuitry of addiction: an overview. British Journal of Pharmacology, 154(2), 261–274.
Fenton, Z. (2003). Project Prevention: cash for birth control, a solution or a violation of rights. The Journal of Law in Society, 5, 199.
Festinger, D. S., Dugosh, K. L., Croft, J. R., et al. (2010). Corrected feedback: a procedure to enhance recall of informed consent to research among substance abusing offenders. Ethics & Behavior, 20, 387–399.
Festinger, D. S., Marlowe, D. B., Croft, J. R., et al. (2009). Monetary incentives improve recall of research consent information: it pays to remember. Experimental and Clinical Psychopharmacology, 17, 99–104.
Festinger, D. S., Ratanadilok, K., Marlowe, D. B., et al. (2007). Neuropsychological functioning and recall of research consent information among drug court clients. Ethics & Behavior, 17, 163–186.
Fillmore, M. T. (2003). Drug abuse as a problem of impaired control: current approaches and findings. Behavioural and Cognitive Neuroscience Reviews, 2, 179–197.
Fingarette, H. (1988). Heavy Drinking: The Myth of Alcoholism as a Disease. Berkley, CA: University of California Press.
Finnigan, F. and Hammerslay, R. (1992). The effect of alcohol on performance. In A. P. Smith and D. M. Jones (Eds.), Handbook of Human Performance, Health and Performance 2 (pp. 73–126). London: Academic Press.
Fiscella, K., Moore, A., Engerman, J., et al. (2005). Management of opiate detoxification in jails. Journal of Addictive Diseases, 24, 61–71.
Fisch, G. S. (2007). Animal models and human neuropsychiatric disorders. Behavior Genetics, V37, 1–10.
Fischer, H., Tillfors, M., Furmark, T., et al. (2001). Dispositional pessimism and amygdala activity: a PET study in healthy volunteers. Neuroreport, 12, 1635–1638.
Fischer, H., Wik, G. and Fredrikson, M. (1997). Extraversion, neuroticism and brain function: a PET study of personality. Personality and Individual Differences, 23, 345–352.
Fisher, C. B., Oransky, M., Mahadevan, M., et al. (2008). Marginalized populations and drug addiction research: realism, mistrust, and misconception. IRB; A Review of Human Subjects Research, 30, 1–9.
Fishman, M. (2008). Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction, 103, 1399–1401.
Fitzgerald, J. and Hamilton, M. (1996). The consequences of knowing: ethical and legal liabilities in illicit drug research. Social Science and Medicine, 43, 1591–1600.
Flowers, C. R. and Veenstra, D. (2004). The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics, 22, 481–493.
Foddy, B. and Savulescu, J. (2006). Addiction and autonomy: can addicted people consent to the prescription of their drug of addiction?Bioethics, 20, 1–15.
Foltz, E. L. and White, L. E., Jr. (1962). Pain “relief” by frontal cingulumotomy. Journal of Neurosurgery, 19, 89–100.
Forman, R. F., Bovasso, G., Woody, G., et al. (2002). Staff beliefs about drug abuse clinical trials. Journal of Substance Abuse Treatment, 23, 55–60.
Foster, K. R., Wolpe, P. R. and Caplan, A. L. (2003). Bioethics & the brain. IEEE Spectrum, 40, 34–39.
Fox, R. G. (1992). The compulsion of voluntary treatment in sentencing. Criminal Law Journal, 16, 37–54.
Frank, M. J., Samanta, J., Moustafa, A. A., et al. (2007). Hold your horses: impulsivity, deep brain stimulation, and medication in Parkinsonism. Science, 318, 1309–1312.
Franzini, A., Ferroli, P., Leone, M., et al. (2003). Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series. Neurosurgery, 52, 1095–1099; discussion 1099–1101.
Franzini, A., Marras, C., Ferroli, P., et al. (2005). Stimulation of the posterior hypothalamus for medically intractable impulsive and violent behavior. Stereotactic and Functional Neurosurgery, 83, 63–66.
Fry, C. and Dwyer, R. (2001). For love or money? An exploratory study of why injecting drug users participate in research. Addiction, 96, 1319–1325.
Fry, C., Hall, W., Ritter, A., et al. (2006). The ethics of paying drug users who participate in research: a review and practical recommendations. Journal of Empirical Research on Human Research Ethics, 1, 21–36.
Fukuyama, F. (2002). Our Posthuman Future: Consequences of the Biotechnology Revolution. London: Profile Books.
Fureman, I., Meyers, K., McLellan, A. T., et al. (1997). Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV vaccine efficacy trials. AIDS Education and Prevention, 9, 330–341.
Gabriels, L., Cosyns, P., Nuttin, B., et al. (2003). Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatrica Scandinavica, 107, 275–282.
Gahlinger, P. M. (2004). Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. American Family Physician, 69, 2619–2626.
Gallinat, J., Bauer, M. and Heinz, A. (2008). Genes and neuroimaging: advances in psychiatric research. Neurodegenerative Disease, 5, 277–285.
Gao, G., Wang, X., He, S., et al. (2003). Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. Stereotactic and Functional Neurosurgery, 81, 96–104.
Garavan, H., Lingford-Hughes, A., Jones, T., et al. (2007). Neuroimaging. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 285–314). London: Academic Press.
Garavan, H. and Stout, J. C. (2005). Neurocognitive insights into substance abuse. Trends in Cognitive Sciences, 9, 195–201.
Garbutt, J. C., Kranzler, H. R., O'Malley, S. S., et al. (2005). Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA, 293, 1617–1625.
Gartner, C. E., Barendregt, J. J. and Hall, W. (2009). Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction, 104, 118–126.
Gartner, C. E., Hall, W., Vos, T., et al. (2007). Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet, 369, 2010–2014.
Gastfriend, D. R. (2011). Intramuscular extended-release naltrexone: current evidence. Annals of the New York Academy of Sciences, 1216, 144–166.
Geppert, C. M. A. and Roberts, L. W. (2005). Ethical issues in the use of genetic information in the workplace: a review of recent developments. Current Opinion in Psychiatry, 18, 518–524.
Gerstein, D. R. and Harwood, H. J. (1990). Treating Drug Problems (Volume 1). A Study of Effectiveness and Financing of Public and Private Drug Treatment Systems. Washington, DC: Institute of Medicine, National Academy Press.
Geyer, M. A. and Markou, A. (1995). Animal models of psychiatric disorders. In F. E. Bloom and D.J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 787–798). New York: Raven.
Gibson, A. E. and Degenhardt, L. J. (2007). Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug and Alcohol Review, 26, 405–410.
Gibson, A. E., Degenhardt, L. J. and Hall, W. (2007). Opioid overdose deaths can occur in patients with naltrexone implants. Medical Journal of Australia, 186, 152–153.
Gieringer, D. H. (2003). The acceptance of medicinal marijuana in the US. Journal of Cannabis Therapeutics, 3, 53–65.
Gillett, G. (2008). Subjectivity and Being Somebody: Human Identity and Neuroethics. Exeter, UK: Imprint Academic.
Gilmore, N. (1995). Drug use and human rights: privacy, vulnerability, disability and human rights infringements. Journal of Contemporary Health Law and Policy, 12, 355–447.
Giordano, J. and Gordijn, B. (2010). Scientific and Philosophical Perspectives in Neuroethics. New York: Cambridge University Press.
Gisquet, E. (2008). Cerebral implants and Parkinson's disease: a unique form of biographical disruption?Social Science and Medicine, 67, 1847–1851.
Glannon, W. (2006a). Bioethics and the Brain. New York: Oxford University Press.
Glannon, W. (2006b). Psychopharmacology and memory. Journal of Medical Ethics, 32, 74–78.
Glick, S. D., Maisonneuve, I. M., Kitchen, B. A., et al. (2002). Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. European Journal of Pharmacology, 438, 99–105.
Goff, P. (2005). ‘I was conscious as they pushed the needle deep into my brain’. The Telegraph. Available at: (Accessed 6 July 2007.)
Gogtay, N., Giedd, J. N., Lusk, L., et al. (2004). Dynamic mapping of human cortical development during childhood through early adulthood. Proceedings of the National Academy of Sciences of the United States of America, 101, 8174–8179.
Gold, C. G., Cullen, D. J., Gonzales, S., et al. (1999). Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology, 91, 1639–1647.
Gold, L. H. and Koob, G. F. (1989). MDMA produces stimulant-like conditioned locomotor activity. Psychopharmacology, 99, 352–356.
Goldman, D., Oroszi, G. and Ducci, F. (2005). The genetics of addictions: uncovering the genes. Nature Reviews. Genetics, 6, 521–532.
Goldstein, A. and Herrera, J. (1995). Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug and Alcohol Dependence, 40, 139–150.
Goldstein, A. and Kalant, H. (1990). Drug policy: striking the right balance. Science, 249, 1513–1521.
Goldstein, R. Z., Alia-Klein, N., Tomasi, D., et al. (2007). Is decreased prefrontal cortical sensitivity to monetary reward associated with impaired motivation and self-control in cocaine addiction?American Journal of Psychiatry, 164, 43–51.
Goldstein, R. Z., Craig, A. D., Bechara, A., et al. (2009). The neurocircuitry of impaired insight in drug addiction. Trends in Cognitive Sciences, 13, 372–380.
Goldstein, R. Z. and Volkow, N. D. (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. American Journal of Psychiatry, 159, 1642–1652.
Gonzalez, G., Oliveto, A. and Kosten, T. R. (2004). Combating opiate dependence: a comparison among the available pharmacological options. Expert Opinion on Pharmacotherapy, 5, 713–725.
Goodman, A. (2008). Neurobiology of addiction: an integrative review. Biochemical Pharmacology, 75, 266–322.
Gorelick, D., Pickens, R. W. and Benkovsky, F. O. (1999). Clinical research in substance abuse: human subjects issues. In H. A. Pinchus, J. A. Lieberman and S. Ferris (Eds.), Ethics in Psychiatric Research: A Resource Manual for Human Subjects' Protection (pp. 177–194). Washington, DC: American Psychiatric Association.
Gostin, L. O. (1993). Compulsory treatment for drug-dependent persons: justifications for a public health approach to drug dependency. In R. Bayer and G. M. Oppenheimer (Eds.), Confronting Drug Policy: Illicit Drugs in a Free Society (pp. 561–593). Cambridge, UK: Cambridge University Press.
Gostin, L. O. (2001). Beyond moral claims: a human rights approach in mental health. Cambridge Quarterly of Healthcare Ethics, 10, 264–274.
Gostin, L. O. and Mann, J. M. (1999). Toward a development of a human rights impact assessment for the formulation and evaluation of public health policies. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 54–72). London: Routledge.
Goudriaan, A., Grekin, E. R. and Sher, K. J. (2008a). The predictive value of neurocognitive decision-making for heavy alcohol use in a longitudinal, prospective study. European Neuropsychopharmacology, 18, S69–S70.
Goudriaan, A., Oosterlaan, J., De Beurs, E., et al. (2008b). The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychological Medicine, 38, 41–50.
Gowing, L., Ali, R. and White, J. (2006). Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database of Systematic Reviews, CD002022.
Gowing, L., Ali, R. and White, J. M. (2009). Buprenorphine for the management of opioid withdrawal. Cochrane Database of Systematic Reviews, CD002025.
Granfield, R. and Cloud, W. (1996). The elephant that no one sees: natural recovery among middle-class addicts. Journal of Drug Issues, 26, 45–61.
Grant, J. E., Brewer, J. A. and Potenza, M. N. (2006). The neurobiology of substance and behavioral addictions. CNS Spectrums, 11, 924.
Grant, J. E., Odlaug, B. L., Potenza, M. N., et al. (2010). Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. British Journal of Psychiatry, 197, 330–331.
Grant, S., Contoreggi, C. and London, E. D. (2000). Drug abusers show impaired performance in a laboratory test of decision making. Neuropsychologia, 38, 1180–1187.
Greely, H. (2001). Genotype discrimination: the complex case for some legislative protection. University of Pennsylvania Law Review, 149, 1438–1505.
Greely, H., Sahakian, B., Harris, J., et al. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456, 702–705.
Greenberg, B. D., Malone, D. A., Friehs, G. M., et al. (2006). Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology, 31, 2384–2393.
Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 376, 595–605.
Grisso, T. and Applebaum, P. S. (1998). Assessing Competence to Consent to Treatment: A Guide for Physicians and Other Health Professionals. New York: Oxford University Press.
Guichard, A., Lert, F., Brodeur, J. M., et al. (2007). Buprenorphine substitution treatment in France: drug users' views of the doctor–user relationship. Social Science & Medicine, 64, 2578–2593.
Gundle, K. R., Dingel, M. J. and Koenig, B. A. (2010). ‘To prove this is the industry's best hope’: big tobacco's support of research on the genetics of nicotine addiction. Addiction, 105, 974–983.
Haga, S. B., Khoury, M. J. and Burke, W. (2003). Genomic profiling to promote a healthy lifestyle: not ready for prime time. Nature Genetics, 34, 347–350.
Hall, L. L. (1996). The human implications of psychiatric genetics. In L. L. Hall (Ed.), Genetics and Mental Illness: Evolving Issues for Research and Society (pp. 157–188). New York, NY: Plenum Press.
Hall, M. A. and Rich, S. S. (2000). Laws restricting health insurers' use of genetic information: impact on genetic discrimination. American Journal of Human Genetics, 66, 293–307.
Hall, W. (1997a). The recent Australian debate about the prohibition on cannabis use. Addiction, 92, 1109–1116.
Hall, W. (1997b). The role of legal coercion in the treatment of offenders with alcohol and heroin problems. Australian and New Zealand Journal of Criminology, 30, 103–120.
Hall, W. (2000). UROD: an antipodean therapeutic enthusiasm. Addiction, 95, 1765–1766.
Hall, W. (2002a). The prospects for immunotherapy in smoking cessation. Lancet, 360, 1089–1091.
Hall, W. (2002b). Taking Darwin seriously: more than telling “just so” stories. Addiction, 97, 472–473.
Hall, W. (2004). Feeling ‘better than well’: can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods?EMBO Reports, 5, 1105–1109.
Hall, W. (2005a). British drinking: a suitable case for treatment?British Medical Journal, 331, 527–528.
Hall, W. (2005b). Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?PLoS Medicine, 2, e266; quiz e351.
Hall, W. (2006a). The regulatory challenges in engineering a safer tipple. Journal of Psychopharmacology, 20, 321–322.
Hall, W. (2006b). Stereotactic neurosurgical treatment of addiction: minimising the chances of another ‘great and desperate cure’. Addiction, 101, 1–3.
Hall, W. (2007). A research agenda for assessing the potential contribution of genomic medicine to tobacco control. Tobacco Control, 16, 53–58.
Hall, W. (2008). The contribution of research to the development of a national cannabis policy in Australia. Addiction, 103, 712–720.
Hall, W., Capps, B. and Carter, A. (2008). The use of depot naltrexone under legal coercion: the case for caution. Addiction, 103, 1922–1924.
Hall, W. and Carter, L. (2004). Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. Journal of Medical Ethics, 30, 337–340.
Hall, W., Carter, L. and Morley, K. I. (2004a). Neuroscience research on the addictions: a prospectus for future ethical and policy analysis. Addictive Behaviors, 29, 1481–1495.
Hall, W. and Degenhardt, L. (2009). Adverse health effects of non-medical cannabis use. Lancet, 374, 1383–1391.
Hall, W., Doran, C., Degenhardt, L., et al. (2006). Illicit opiate use. In D. T. Jamison (Ed.), Disease Control Priorities in Developing Countries (pp. 907–931). New York: Oxford University Press.
Hall, W., Gartner, C. E. and Carter, A. (2008). The genetics of nicotine addiction liability: ethical and social policy implications. Addiction, 103, 350–359.
Hall, W. and Lucke, J. (2010a). The enhancement use of neuropharmaceuticals: more scepticism and caution needed. Addiction, 105, 2041–2043.
Hall, W. and Lucke, J. (2010b). Legally coerced treatment for drug using offenders: ethical and policy issues. Crime and Justice Bulletin, 144, 1–12.
Hall, W., Madden, P. and Lynskey, M. (2002). The genetics of tobacco use: methods, findings and policy implications. Tobacco Control, 11, 119–124.
Hall, W. and Mattick, R. P. (2000). Is ultra-rapid opioid detoxification a viable option in the treatment of opioid dependence?CNS Drugs, 14, 251–255.
Hall, W., Morley, K. I. and Lucke, J. (2004b). The prediction of disease risk in genomic medicine: scientific prospects and implications for public policy and ethics. EMBO Reports, 5, S22–S26.
Hall, W. and Pacula, R. L. (2003). Cannabis Use and Dependence: Public Health and Public Policy. Cambridge: Cambridge University Press.
Hall, W., Room, R. and Bondy, S. (1999). Comparing the health and psychological risks of alcohol, cannabis, nicotine and opiate use. In H. Kalant, W. Corrigal, W. Hall, et al. (Eds.), The Health Effects of Cannabis (pp. 475–506). Toronto: Centre for Addiction and Mental Health.
Hall, W. and Sannibale, C. (1996). Are there two types of alcoholism?Lancet, 348, 1258.
Hamani, C., McAndrews, M. P., Cohn, M., et al. (2008). Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Annals of Neurology, 63, 119–123.
Hamilton, R. J., Olmedo, R. E., Shah, S., et al. (2002). Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Academic Emergency Medicine, 9, 63–68.
Hando, J. and Darke, S. (1998). NSW Drug Trends 1997. Findings from the Illicit Drug Reporting System (IDRS). National Drug and Alcohol Research Centre Technical Report 56. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
Harrison, K., Vlahov, D., Jones, K., et al. (1995). Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 10, 386–390.
Harwood, H. J. and Myers, T. G. (2004). New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: National Academies Press.
Hasin, D. S. (1994). Treatment/self-help for alcohol-related problems: relationship to social pressure and alcohol dependence. Journal of Studies on Alcohol, 55, 660–666.
Hasman, A. and Holm, S. (2004). Nicotine conjugate vaccine: is there a right to a smoking future?Journal of Medical Ethics, 30, 344–345.
Hauser, M. D. (2006). Moral Minds: How Nature Designed our Universal Sense of Right and Wrong. New York: Ecco.
Hawkins, J. D., Catalano, R. F. and Miller, J. Y. (1992). Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychological Bulletin, 112, 64–105.
Hazelton, L. D., Sterns, G. L. and Chisholm, T. (2003). Decision-making capacity and alcohol abuse: clinical and ethical considerations in personal care choices. General Hospital Psychiatry, 25, 130–135.
Healy, D. (2002). The Creation of Psychopharmacology. Cambridge, MA: Harvard University Press.
Healy, D. (2004). Let Them Eat Prozac: The Unhealthy Relationship Between the Pharmaceutical Industry and Depression. New York: New York University Press.
Heinz, A., Reimold, M., Wrase, J., et al. (2005). Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Archives of General Psychiatry, 62, 57–64.
Heinze, H. J., Heldmann, M., Voges, J., et al. (2009). Counteracting incentive sensitization in severe alcohol dependence using deep brain stimulation of the nucleus accumbens: clinical and basic science aspects. Frontiers in Human Neuroscience, 3, 22.
Heinzerling, K. G., Swanson, A.-N., Kim, S., et al. (2010). Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug and Alcohol Dependence, 109, 20–29.
Hejazi, N. S. (2007). Pharmacogenetic aspects of addictive behaviors. Dialogues in Clinical Neuroscience, 9, 447–454.
Helfand, W. H. (1996). Selling addiction cures. Transactions and Studies of the College of Physicians of Philadelphia, 18, 85–108.
Herz, A. (1997). Endogenous opioid systems and alcohol addiction. Psychopharmacology, 129, 99–111.
Hester, R. and Garavan, H. (2004). Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. Journal of Neuroscience, 24, 11017–11022.
Heyman, G. (2009). Addiction: A Disorder of Choice. Cambridge, MA: Harvard University Press.
Higgins, S. T. (2006). Extending contingency management to the treatment of methamphetamine use disorders. American Journal of Psychiatry, 163, 1870–1872.
Higgins, S. T., Delaney, D. D., Budney, A. J., et al. (1991). A behavioral approach to achieving initial cocaine abstinence. American Journal of Psychiatry, 148, 1218–1224.
Higgins, S. T. and Petry, N. M. (1999). Contingency management. Incentives for sobriety. Alcohol Research and Health, 23, 122–127.
Hill, E. M. and Newlin, D. B. (2002). Evolutionary approaches to addiction: introduction. Addiction, 97, 375–379.
Ho, M. K., Goldman, D., Heinz, A., et al. (2010). Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clinical Pharmacology and Therapeutics, 88, 779–791.
Hoff, N., Evers-Casey, S., Weibel, S., et al. (2005). Impact of genetic risk information on smokers' motivation to quit. RP-062, S16. 11th Annual Meeting of the Society for Research on Nicotine and Tobacco. Prague, Czech Republic.
Holden, C. (2001). ‘Behavioral’addictions: do they exist?Science, 294, 980–982.
Holtzman, N. A. and Marteau, T. M. (2000). Will genetics revolutionize medicine?New England Journal of Medicine, 343, 141–144.
Horka-Ruiz, J. (2000). Preventing the birth of drug-addicted babies through contract: an examination of the CRACK Organization. William and Mary Journal of Women and the Law, 7, 473.
Hotopf, M. (2005). The assessment of mental capacity. Clinical Medicine, 5, 580–584.
Hotze, T. D., Shah, K., Anderson, E. E., et al. (2011). “Doctor, would you prescribe a pill to help me. . .?” A national survey of physicians on using medicine for human enhancement. The American Journal of Bioethics, 11, 3–13.
Hubbard, R. L., Collins, J. J., Rachal, J. H., et al. (1988). The criminal justice client in drug abuse treatment. In C. Leukefeld and F. M. Tims (Eds.), Compulsory Treatment of Drug Abuse: Research and Clinical Practice. Rockville, MD: National Institute of Drug Abuse.
Hughes, J. R. (2009). Smokers' beliefs about the inability to stop smoking. Addictive Behaviors, 34, 1005–1009.
Hulse, G. K., Arnold-Reed, D. E., O'Neil, G., et al. (2004). Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants. Addiction Biology, 9, 67–72.
Hulse, G. K., English, D. R., Milne, E., et al. (1999). The quantification of mortality resulting from the regular use of illicit opiates. Addiction, 94, 221–229.
Hulse, G. K., Stalenberg, V., McCallum, D., et al. (2005). Histological changes over time around the site of sustained release naltrexone-poly(DL-lactide) implants in humans. Journal of Controlled Release, 108, 43–55.
Hume, D. (1978). A Treatise of Human Nature. Oxford: Oxford University Press.
Husak, D. N. (1992). Drugs and Rights. Cambridge, England: Cambridge University Press.
Hutcheson, D. M., Everitt, B. J., Robbins, T. W., et al. (2001). The role of withdrawal in heroin addiction: enhances reward or promotes avoidance?Nature Neuroscience, 4, 943–947.
Hutchison, K. E. (2010). Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. Annual Review of Clinical Psychology, 6, 577–589.
Huxley, A. (1954). The Doors of Perception. New York: Harper.
Hyman, S. E. (2005). Addiction: a disease of learning and memory. American Journal of Psychiatry, 162, 1414–1422.
Hyman, S. E. (2007). The neurobiology of addiction: implications for voluntary control of behavior. American Journal of Bioethics, 7, 8–11.
Hyman, S. E., Malenka, R. C. and Nestler, E. J. (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annual Review of Neuroscience, 29, 565–598.
Illes, J. (2003). Neuroethics in a new era of neuroimaging. American Journal of Neuroradiology, 24, 1739–1741.
Illes, J. (2006). Neuroethics: Defining the Issues in Theory, Practice, and Policy. Oxford: Oxford University Press.
Illes, J. (2007). Empirical neuroethics. Can brain imaging visualize human thought? Why is neuroethics interested in such a possibility?EMBO Reports, 8 Spec No, S57–60.
Illes, J., Kirschen, M. P., Edwards, E., et al. (2006). Ethics. Incidental findings in brain imaging research. Science, 311, 783–784.
Illes, J., Kirschen, M. P., Karetsky, K., et al. (2004a). Discovery and disclosure of incidental findings in neuroimaging research. Journal of Magnetic Resonance Imaging, 20, 743–747.
Illes, J. and Racine, E. (2005). Imaging or imagining? A neuroethics challenge informed by genetics. American Journal of Bioethics, 5, 5–18.
Illes, J., Rosen, A., Greicius, M., et al. (2007). Prospects for prediction: ethics analysis of neuroimaging in Alzheimer's disease. Annals of the New York Academy of Sciences, 1097, 278–295.
Illes, J., Rosen, A. C., Huang, L., et al. (2004b). Ethical consideration of incidental findings on adult brain MRI in research. Neurology, 62, 888–890.
Insel, T. R. (2009). Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Archives of General Psychiatry, 66, 128–133.
International Federation of Red Cross and Red Crescent Societies and Francois-Xavier Bagnoud Center for Health and Human Rights. (1999). Human rights: an introduction. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 21–28). London: Routledge.
Ioannidis, J. P. (2011). Excess significance bias in the literature on brain volume abnormalities. Archives of General Psychiatry, 10.1001/archgenpsychiatry.2011.28.
Ito, H., Matsuo, K., Wakai, K., et al. (2006). An intervention study of smoking cessation with feedback on genetic cancer susceptibility in Japan. Preventive Medicine, 42, 102–108.
Iversen, L. (2002). The Science of Marijuana. Oxford: Oxford University Press.
Iversen, S. and Iversen, L. (2007). Dopamine: 50 years in perspective. Trends in Neurosciences, 30, 188–193.
Iverson, L., Morris, K. and Nutt, D. (2007). Pharmacology and treatments. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 169–208). London: Academic Press.
Jayaram-Lindstrom, N., Hammarberg, A., Beck, O., et al. (2008). Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. American Journal of Psychiatry, 165, 1442–1448.
Jentsch, J. D. and Taylor, J. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology, 146, 373–390.
Jeste, D. V. and Saks, E. (2006). Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behavioral Sciences and the Law, 24, 607–628.
John, U., Meyer, C., Hapke, U., et al. (2004). Nicotine dependence, quit attempts, and quitting among smokers in a regional population sample from a country with a high prevalence of tobacco smoking. Preventive Medicine, 38, 350–358.
Johnson, B. A., Rosenthal, N., Capece, J. A., et al. (2007). Topiramate for treating alcohol dependence: a randomized controlled trial. Journal of the American Medical Association, 298, 1641–1651.
Joint Committee of the American Bar Association and the American Medical Association on Narcotic Drugs. (1961). Drug Addiction: Crime or Disease. Bloomington: Indiana University Press.
Joly, Y., Braker, M. and Le Huynh, M. (2010). Genetic discrimination in private insurance: global perspectives. New Genetics and Society, 29, 351–368.
Jonsen, A. R. (1998). The Birth of Bioethics. New York: Oxford University Press.
Jorenby, D. E., Leischow, S. J., Nides, M. A., et al. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine, 340, 685–691.
Jupp, B. and Lawrence, A. J. (2009). New horizons for therapeutics in drug and alcohol abuse. Pharmacology and Therapeutics, 125(1), 138–168.
Jurgens, R. and Betteridge, G. (2005). Prisoners who inject drugs: public health and human rights imperatives. Health and Human Rights, 8, 46–74.
Kagan, J. (2006). An Argument for Mind. London: Yale University Press.
Kalant, H. (2010). What neurobiology cannot tell us about addiction. Addiction, 105, 780–789.
Kalivas, P. W. and Volkow, N. D. (2005). The neural basis of addiction: a pathology of motivation and choice. American Journal of Psychiatry, 162, 1403–1413.
Kampman, K. M., Pettinati, H., Lynch, K. G., et al. (2004). A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence, 75, 233–240.
Kampman, K. M., Volpicelli, J. R., Mulvaney, F., et al. (2001). Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug and Alcohol Dependence, 63, 69–78.
Kanaka, T. S. and Balasubramaniam, V. (1978). Stereotactic cingulumotomy for drug addiction. Applied Neurophysiology, 41, 86–92.
Kandel, E. (2006). In Search of Memory: The Emergence of a New Science of Mind. New York: W.W. Norton.
Kant, I. (1996). The Metaphysics of Morals. New York: Cambridge University Press.
Kantak, K. M. (2003). Vaccines against drugs of abuse: a viable treatment option?Drugs, 63, 341–352.
Karila, L., Weinstein, A., Aubin, H. -J., et al. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. British Journal of Clinical Pharmacology, 69, 578–592.
Kariminia, A., Law, M. G., Butler, T. G., et al. (2007). Suicide risk among recently released prisoners in New South Wales, Australia. Medical Journal of Australia, 187, 387–390.
Kass, L. (2002). Life, Liberty and the Defense of Dignity. San Francisco, CA: Encounter Books.
Kauer, J. and Malenka, R. C. (2007). Synaptic plasticity and addiction. Nature Reviews. Neuroscience, 8, 844–858.
Keane, H. (2005). Moral frameworks, ethical engagement and harm reduction: commentary on “Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics” by C. L. Fry, C. Treloar and L. Maher. Drug and Alcohol Review, 24, 551–552.
Kelley, A. E. (2004). Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron, 44, 161–179.
Kelley, A. E. and Berridge, K. C. (2002). The neuroscience of natural rewards: relevance to addictive drugs. Journal of Neuroscience, 22, 3306–3311.
Kelman, H. (1964). Narcotic Withdrawal Syndrome. Suppression of by means of electric convulsive therapy. Minnesota Medicine, 47, 525–527.
Kenney, C., Simpson, R., Hunter, C., et al. (2007). Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. Journal of Neurosurgery, 106, 621–625.
Kessler, R. C., Berglund, P. M., Demler, O. M., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62, 593–602.
Khantzian, E. J. (1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259–1264.
Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Review of Psychiatry, 4, 231–244.
Khoury, M. J., McCabe, L. L. and McCabe, E. R. B. (2003). Genomic medicine: population screening in the age of genomic medicine. New England Journal of Medicine, 348, 50–58.
Khoury, M. J., Thrasher, J. F., Burke, W., et al. (2000). Challenges in communicating genetics: a public health approach. Genetics in Medicine, 2, 198–202.
Khoury, M. J., Yang, Q. H., Gwinn, M., et al. (2004). An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Genetics in Medicine, 6, 38–47.
Kilts, C. D., Schweitzer, J. B., Quinn, C. K., et al. (2001). Neural activity related to drug craving in cocaine addiction. Archives of General Psychiatry, 58, 334–341.
Kiluk, B. D., Nich, C. and Carroll, K. M. (2010). Neurocognitive indicators predict results of an informed-consent quiz among substance-dependent treatment seekers entering a randomized clinical trial. Journal of Studies on Alcohol and Drugs, 71, 704–712.
Kirchmayer, U., Davoli, M. and Verster, A. (2003). Naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD001333.
Kirulis, K. and Zacny, J. (1998). Do healthy volunteers increase drug usage after participation in research involving opioids and nitrous oxide?Anesthesiology, 89, 1222.
Kisely, S. (2008). The case for policy reform in cannabis control. Canadian Journal of Psychiatry, 53, 795–797.
Klag, S., O'Callaghan, F. and Creed, P. (2005). The use of legal coercion in the treatment of substance abusers: an overview and critical analysis of thirty years of research. Substance Use & Misuse, 40, 1777–1795.
Kleber, H. D. and Riordan, C. E. (1982). The treatment of narcotic withdrawal: a historical review. Journal of Clinical Psychiatry, 43, 30–34.
Kleiman, M. (1992). Against Excess: Towards a Drug Policy that Works. New York: Basic Books.
Kleinig, J. (1985). Ethical Issues in Psychosurgery. London: Allen & Unwin.
Kleinig, J. (2004). Ethical issues in substance use intervention. Substance Use & Misuse, 39, 369–398.
Klingemann, H. and Bergmark, A. (2006). The legitimacy of addiction treatment in a world of smart people. Addiction, 101, 1230–1237.
Knapp, C. M., Tozier, L., Pak, A., et al. (2009). Deep brain stimulation of the nucleus accumbens reduces ethanol consumption in rats. Pharmacology, Biochemistry & Behavior, 92, 474–479.
Knight, G. (1969). Chronic depression and drug addiction treated by stereotactic surgery. Nursing Times, 65, 583–586.
Knightly, P. (1979). Suffer the Children: The Story of Thalidomide. New York: The Viking Press.
Kolb, L. and Himmelsbach, C. K. (1938). Clinical studies of drug addiction III: a critical review of the withdrawal treatments with method of evaluating abstinence syndromes. American Journal of Psychiatry, 94, 759–799.
Koob, G. F. (1999). Stress, corticotropin-releasing factor, and drug addiction. Annals of the New York Academy of Sciences, 897, 27–45.
Koob, G. F. (2008). A role for brain stress systems in addiction. Neuron, 59, 11–34.
Koob, G. F. and Bloom, F. E. (1988). Cellular and molecular mechanisms of drug dependence. Science, 242, 715–723.
Koob, G. F. and Kreek, M. J. (2007). Stress, dysregulation of drug reward pathways, and the transition to drug dependence. American Journal of Psychiatry, 164, 1149–1159.
Koob, G. F. and Le Moal, M. (1997). Drug abuse: hedonic homeostatic dysregulation. Science, 278, 52–58.
Koob, G. F. and Le Moal, M. (2005). Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nature Neuroscience, 8, 1442–1444.
Koob, G. F. and Le Moal, M. (2006). Neurobiology of Addiction. New York: Academic Press.
Koob, G. F. and Le Moal, M. (2008). Addiction and the brain antireward system. Annual Review of Psychology, 59, 29–53.
Koob, G. F., Lloyd, G. K. and Mason, B. J. (2009). Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nature Reviews Drug Discovery, 8, 500–515.
Korf, D. J. (2002). Dutch coffee shops and trends in cannabis use. Addictive Behaviors, 27, 851–866.
Kosfeld, M., Heinrichs, M., Zak, P. J., et al. (2005). Oxytocin increases trust in humans. Nature, 435, 673–676.
Kosten, T. and Owens, S. M. (2005). Immunotherapy for the treatment of drug abuse. Pharmacology & Therapeutics, 108, 76–85.
Kosten, T., Rosen, M., Bond, J., et al. (2002). Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine, 20, 1196–1204.
Krack, P., Hariz, M. I., Baunez, C., et al. (2010). Deep brain stimulation: from neurology to psychiatry?Trends in Neurosciences, 33, 474–484.
Kranzler, H. R., Dolinsky, Z. and Kaplan, R. F. (1990). Giving ethanol to alcoholics in a research setting: its effect on compliance with disulfiram treatment. British Journal of Addiction, 85, 119–123.
Kranzler, H. R., Modesto-Lowe, V. and Nuwayser, E. S. (1998). Sustained-release naltrexone for alcoholism treatment: a preliminary study. Alcoholism, Clinical and Experimental Research, 22, 1074–1079.
Krupitsky, E. and Blokhina, E. A. (2010). Long-acting depot formulations of naltrexone for heroin dependence: a review. Current Opinion in Psychiatry, 23(3), 210–214.
Krupitsky, E., Zvartau, E., Masalov, D. V., et al. (2004). Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 26, 285–294.
Krupitsky, E., Zvartau, E. and Woody, G. (2010). Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Current Psychiatry Reports, 12, 448–453.
Kruptisky, E. M., Burakov, A. M., Tsoy, M. V., et al. (2007). Overcoming opioid blockade from depot naltrexone (Prodetoxon®). Addiction, 102, 1164–1165.
Kuehn, B. M. (2009). Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA, 301, 1007–1008.
Kuhn, J., Bauer, R., Pohl, S., et al. (2009). Observations on unaided smoking cessation after deep brain stimulation of the nucleus accumbens. European Addiction Research, 15, 196–201.
Kuhn, J., Lenartz, D., Huff, W., et al. (2007). Remission of alcohol dependency following deep brain stimulation of the nucleus accumbens: valuable therapeutic implications?Journal of Neurology, Neurosurgery and Psychiatry, 78, 1152–1153.
Kunoe, N., Lobmaier, P., Vederhus, J. K., et al. (2009). Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 194, 541–546.
Lahti, T., Halme, J. T., Pankakoski, M., et al. (2010). Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacology Bulletin, 43, 35–44.
Lanteri, C., Salomon, L., Torrens, Y., et al. (2008). Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology, 33, 1724–1734.
LaRowe, S. D., Mardikian, P., Malcolm, R., et al. (2006). Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. The American Journal of Addictions, 15, 105–110.
Larriviere, D., Williams, M. A., Rizzo, M., et al. (2009). Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. Neurology, 73, 1406–1412.
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., et al. (1995). SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of Nuclear Medicine, 36, 1182–1190.
Lawford, B. R., Young, R. M., Noble, E. P., et al. (2000). The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. American Journal of Medical Genetics, 96, 592–598.
Leader, A. E., Lerman, C. and Cappella, J. N. (2010). Nicotine vaccines: will smokers take a shot at quitting?Nicotine and Tobacco Research, 12, 390–397.
Lee, A. M. and Tyndale, R. F. (2006). Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. Journal of Psychopharmacology, 20, 7–14.
Lerman, C. and Berrettini, W. (2003). Elucidating the role of genetic factors in smoking behavior and nicotine dependence. American Journal of Medical Genetics, 118, 48–54.
Lerman, C., Gold, K., Audrain, J., et al. (1997). Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking related cognitions, emotions and behavior change. Health Psychology, 16, 87–99.
Leshner, A. I. (1997). Addiction is a brain disease, and it matters. Science, 278, 45–47.
Leshner, A. I. (2005). It's time to go public with neuroethics. American Journal of Bioethics, 5, 1–2.
Leukefeld, C. G. and Tims, F. M. (1988). Compulsory Treatment of Drug Abuse: Research and Clinical Practice. Rockville, MD: National Institute on Drug Abuse.
Levin, F. R., Evans, S. M., Brooks, D. J., et al. (2007). Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug and Alcohol Dependence, 87, 20–29.
Levy, D., Shabat-Simon, M., Shalev, U., et al. (2007). Repeated electrical stimulation of reward-related brain regions affects cocaine but not “natural” reinforcement. Journal of Neuroscience, 27, 14179–14189.
Levy, N. (2006a). Addiction, autonomy and ego-depletion: a response to Bennett Foddy and Julian Savulescu. Bioethics, 20, 16–20.
Levy, N. (2006b). Autonomy and addiction. Canadian Journal of Philosophy, 36, 427–448.
Levy, N. (2007). Neuroethics: Challenges for the 21st Century. Cambridge: Cambridge University Press.
Levy, N. and Clarke, S. (2008). Neuroethics and psychiatry. Current Opinion in Psychiatry, 21, 568–571.
Li, M. D. and Burmeister, M. (2009). New insights into the genetics of addiction. Nature Reviews. Genetics, 10, 225–231.
Lim, S. Y., O'Sullivan, S. S., Kotschet, K., et al. (2009). Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. Journal of Clinical Neuroscience, 16, 1148–1152.
Ling, W., Casadonte, P., Bigelow, G., et al. (2010). Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA, 304, 1576–1583.
Ling, W. and Compton, P. (2005). Recent advances in the treatment of opiate addiction. Clinical Neuroscience Research, 5, 161–167.
Lingford-Hughes, A. and Nutt, D. (2003). Neurobiology of addiction and implications for treatment. British Journal of Psychiatry, 182, 97–100.
Lingford-Hughes, A., Welch, S. and Nutt, D. (2004). Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 18, 293–335.
Lipsman, N., Neimat, J. S. and Lozano, A. M. (2007). Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery, 61, 1–11; discussion 11–13.
Liu, H. Y., Jin, J., Tang, J. S., et al. (2008). Chronic deep brain stimulation in the rat nucleus accumbens and its effect on morphine reinforcement. Addiction Biology, 13, 40–46.
Loimer, N., Schmid, R., Lenz, K., et al. (1990). Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. British Journal of Psychiatry, 157, 748–752.
Loimer, N., Schmid, R., Presslich, O., et al. (1988). Naloxone treatment for opiate withdrawal syndrome. British Journal of Psychiatry, 153, 851–852.
Lu, L., Wang, X. and Kosten, T. R. (2009). Stereotactic neurosurgical treatment of drug addiction. American Journal of Drug and Alcohol Abuse, 35, 391–393.
Lubman, D., Hides, L., Yücel, M., et al. (2007a). Intervening early to reduce developmentally harmful substance use among youth populations. Medical Journal of Australia, 187, S22–25.
Lubman, D., Yucel, M. and Hall, W. (2007b). Substance use and the adolescent brain: a toxic combination?Journal of Psychopharmacology, 21, 792–794.
Lucke, J., Bell, S., Partridge, B., et al. (2011a). Academic doping or Viagra for the brain? The history of recreational drug use and pharmacological enhancement can provide insight into these uses of neuropharmaceuticals. EMBO Reports, 12, 197–201.
Lucke, J., Bell, S., Partridge, B., et al. (2011b). Deflating the neuroenhancement bubble. American Journal of Bioethics – Neuroscience, in press.
Lucke, J., Diedrichs, P. C., Partridge, B., et al. (2009). Anticipating the anti-ageing pill. Lessons from the history of the oral contraceptive pill and hormone replacement therapy. EMBO Reports, 10, 108–113.
Lynskey, M. and Hall, W. (2001). Attention Deficit Hyperactivity Disorder and substance use disorders: is there a causal link?Addiction, 96, 815–822.
Lysaught, M. T. (2004). Respect: or, how respect for persons became respect for autonomy. Journal of Medicine and Philosophy, 29, 665–680.
Lyvers, M. and Yakimoff, M. (2003). Neuropsychological correlates of opioid dependence and withdrawal. Addictive Behaviors, 28, 605–611.
Maastricht University Medical Center. (2009). A phase 2B, multi-center, randomized, double-blinded, parallel-arm study to assess efficacy and safety of 3'′-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) as an aid in smoking cessation. Available at: (Accessed 6 October 2010.)
MacCoun, R. (2004). Anticipating unintended consequences of vaccine-like immunotherapies and depot medications of addictive drug use. In H. J. Harwood and T. G. Myers (Eds.), New Treatments for Addiction: Behavioral, Ethical, Legal and Social Questions (pp. 241–275). Washington, DC: National Academies Press.
MacCoun, R. and Reuter, P. (1997). Interpreting Dutch cannabis policy: reasoning by analogy in the legalization debate. Science, 278, 47.
MacCoun, R. and Reuter, P. (2001). Drug-war Heresies: Learning from Other Vices, Times and Places. Cambridge: Cambridge University Press.
Machii, K., Cohen, D., Ramos-Estebanez, C., et al. (2006). Safety of rTMS to non-motor cortical areas in healthy participants and patients. Clinical Neurophysiology, 117, 455–471.
MacIntyre, A. (1985). After Virtue: A Study in Moral Theory. London: Duckwirth.
MacIntyre, A. (1998). A Short History of Ethics: A History of Moral Philosophy from the Homeric Age to the Twentieth Century. Notre Dame, IN: University of Notre Dame Press.
Madden, R. G. (1996). Civil commitment for substance abuse by pregnant women? A view from the front lines. Politics and the Life Sciences, 15, 56–59.
Maddux, J. (1988). Clinical experience with civil commitment. In C. G. Leukefeld and F. M. Tims (Eds.), Compulsory Treatment of Drug Abuse: Research and Clinical Experience (Vol. 86, pp. 35–56). Rockville, MD: National Institute on Drug Addiction.
Maher, B. (2008). Poll results: look who's doping. Nature, 452, 674–675.
Maldonado, R. (1997). Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neuroscience and Biobehavioral Reviews, 21, 91–104.
Mann, J. M. (1997). Medicine and public health, ethics and human rights. Hastings Center Report, 27, 6–13.
Mann, J. M. (1999). Health and human rights. In J. M. Mann (Ed.), Health and Human Rights: A Reader (pp. 7–20). London: Routledge.
Mantione, M., van de Brink, W., Schuurman, P. R., et al. (2010). Smoking cessation and weight loss after chronic deep brain stimulation of the nucleus accumbens: therapeutic and research implications: case report. Neurosurgery, 66, E218; discussion E218.
Marcus, S. (Ed.). (2002). Neuroethics: Mapping the Field. Conference Proceedings (13–14 May, 2002). San Fransisco: The Dana Foundation.
Mardikian, P. N., LaRowe, S. D., Hedden, S., et al. (2007). An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 31, 389–394.
Marinelli, M. and Piazza, P. V. (2002). Interaction between glucocorticoid hormones, stress and psychostimulant drugs. European Journal of Neuroscience, 16, 387–394.
Marlowe, D. B. (2006). Depot naltrexone in lieu of incarceration: a behavioral analysis of coerced treatment for addicted offenders. Journal of Substance Abuse Treatment, 31, 131–139.
Marteau, T., Ashcroft, R. E. and Oliver, A. (2009). Using financial incentives to achieve healthy behaviour. British Medical Journal, 338, 983–985.
Marteau, T. and Lerman, C. (2001). Genetic risk and behavioural change. British Medical Journal, 322, 1056–1059.
Marteau, T., Munafò, M. R., Aveyard, P., et al. (2010). Trial protocol: using genotype to tailor prescribing of nicotine replacement therapy. A randomised controlled trial assessing impact of communication upon adherence. BMC Public Health, 10, 680.
Marteau, T. and Richards, D. (1996). The Troubled Helix: Social and Psychological Implications of the New Human Genetics. New York: Cambridge University Press.
Marteau, T. and Weinman, J. (2006). Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Social Science and Medicine, 62, 1360–1368.
Martell, B. A., Orson, F. M., Poling, J., et al. (2009). Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Archives of General Psychiatry, 66, 1116–1123.
Mathieu, D. (1995). Mandating treatment for pregnant substance abusers: a compromise. Politics and the Life Sciences, 14, 199–208.
Matthew-Simmons, F., Love, S. and Ritter, A. (2008). A Review of Australian Public Opinion Surveys on Illicit Drugs. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
Mattick, R. P., Breen, C., Kimber, J., et al. (2009). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews, 3, CD002209.
Mattick, R. P. and Hall, W. (1996). Are detoxification programmes effective?Lancet, 347, 97–100.
Mattick, R. P., Kimber, J., Breen, C., et al. (2008). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2, CD002207.
Mayberg, H. S., Lozano, A. M., Voon, V., et al. (2005). Deep brain stimulation for treatment-resistant depression. Neuron, 45, 651–660.
Mayor, S. (1997). Specialists criticise treatment for heroin addiction. British Medical Journal, 314, 1365.
Maze, I. and Nestler, E. J. (2011). The epigenetic landscape of addiction. Annals of the New York Academy of Sciences, 1216, 99–113.
McAllister, W. B. (2000). Drug Diplomacy in the Twentieth Century: An International History. London: Routledge.
McBride, C. M., Bepler, G., Lipkus, I. M., et al. (2002). Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. Cancer Epidemiology, Biomarkers and Prevention, 11, 521–528.
McBride, C. M., Bowen, D., Brody, L. C., et al. (2010). Future health applications of genomics: priorities for communication, behavioral, and social sciences research. American Journal of Preventive Medicine, 38, 556–565.
McCabe, D. P. and Castel, A. D. (2008). Seeing is believing: the effect of brain images on judgments of scientific reasoning. Cognition, 107, 343–352.
McClure, S. M., Daw, N. D. and Montague, P. R. (2003). A computational substrate for incentive salience. Trends in Neurosciences, 26, 423–428.
McCrady, B. S. and Bux, D. A., Jr. (1999). Ethical issues in informed consent with substance abusers. Journal of Consulting and Clinical Psychology, 67, 186–193.
McGee, G. (1999). Pragmatic methods and bioethics. In G. McGee (Ed.), Pragmatic Bioethics (pp. 18–29). London: Vanderbilt University Press.
McGregor, I. S., Callaghan, P. D. and Hunt, G. E. (2008). From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?British Journal of Pharmacology, 154, 358–368.
McKeganey, N., Neale, J., Lloyd, C., et al. (2007). Sociology and substance use. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 359–388). London: Academic Press.
McLellan, A. T., Lewis, D. C., O'Brien, C. P., et al. (2000). Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA, 284, 1689–1695.
McLellan, A. T., Skipper, G. S., Campbell, M., et al. (2008). Five year outcomes in a cohort study of physicians treated for substance use disorders in the United States. British Medical Journal, 337, a2038.
McNeely, H. E., Mayberg, H. S., Lozano, A. M., et al. (2008). Neuropsychological impact of Cg25 deep brain stimulation for treatment-resistant depression: preliminary results over 12 months. Journal of Nervous and Mental Disease, 196, 405–410.
Medvedev, S. V., Anichkov, A. D. and Poltakov Iu, I. (2003). Physiological mechanisms of the effectiveness of bilateral stereotactic cingulotomy in treatment of strong psychological dependence in drug addiction. Fiziologiia Cheloveka, 29, 117–123.
Mehta, M. A., Owen, A. M., Sahakian, B. J., et al. (2000). Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. Journal of Neuroscience, 20, RC65.
Merikangas, K. R., Mehta, R. L., Molnar, B. E., et al. (1998). Comorbidity of substance use disorders with mood and anxiety disorders: results of the international consortium in psychiatric epidemiology. Addictive Behaviors, 23, 893–907.
Merikangas, K. R. and Risch, N. (2003). Genomic priorities and public health. Science, 302, 599–601.
Merrick, J. C. (1996). Pregnancy and substance abuse: education or mandatory treatment?Politics and the Life Sciences, 15, 59–60.
Midanik, L. (2006). Biomedicalization of Alcohol Studies: Methodological Shifts and Institutional Challenges. New Brunswick, NJ: Transaction Publishers.
Milekic, M. H., Brown, S. D., Castellini, C., et al. (2006). Persistent disruption of an established morphine conditioned place preference. Journal of Neuroscience, 26, 3010–3020.
Mill, J. S. (2001). Utilitarianism. Indianapolis: Hackett.
Milton, A. L., Lee, J. L. and Everitt, B. J. (2008). Reconsolidation of appetitive memories for both natural and drug reinforcement is dependent on {beta}-adrenergic receptors. Learning and Memory, 15, 88–92.
Minogue, K. and Marshall, E. (2010). Guatemala study from 1940s reflects a ‘dark chapter’ in medicine. Science, 330, 160.
Mintzer, M. Z., Copersino, M. L. and Stitzer, M. L. (2005). Opioid abuse and cognitive performance. Drug and Alcohol Dependence, 78, 225–230.
Mintzer, M. Z. and Stitzer, M. L. (2002). Cognitive impairment in methadone maintenance patients. Drug and Alcohol Dependence, 67, 41–51.
Miotto, K., McCann, M., Basch, J., et al. (2002). Naltrexone and dysphoria: fact or myth?American Journal on Addictions, 11, 151–160.
Modell, J. G., Glaser, F. B. and Mountz, J. M. (1993). The ethics and safety of alcohol administration in the experimental setting to individuals who have chronic, severe alcohol problems. Alcohol and Alcoholism, 28, 189–197.
Montoya, I. D. and Haertzen, C. (1994). Reduction of psychopathology among individuals participating in non-treatment drug abuse residential studies. Journal of Addictive Disorders, 13, 89–97.
Montreal Gazette. (2006). Who rules the medicine cabinet? Montreal Gazette. Available at:
Moore, D., Aveyard, P., Connock, M., et al. (2009). Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. British Medical Journal, 338, b1024.
Moreno, A. Y., Azar, M. R., Warren, N. A., et al. (2010). A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Molecular Pharmaceutics, 7, 431–441.
Moreno, J. D. (1999). Bioethics is a naturalism. In G. McGee (Ed.), Pragmatic Bioethics (pp. 5–17). London: Vanderbilt University Press.
Morgan, D., Grant, K. A., Gage, H. D., et al. (2002). Social dominance in monkeys: dopamine D-2 receptors and cocaine self-administration. Nature Neuroscience, 5, 169–174.
Morley, K. (2008). Modelling Smoking Behaviour: From Genes and Environment to Pharmacoeconomics [Ph.D. thesis]. Brisbane: School of Population Health, The University of Queensland.
Moussawi, K., Pacchioni, A., Moran, M., et al. (2009). N-Acetylcysteine reverses cocaine-induced metaplasticity. Nature Neuroscience, 12(2), 182–189.
Moynihan, R. and Cassels, A. (2005). Selling Sickness: How the Drug Companies are Turning us All Into Patients. Crows Nest, NSW: Allen & Unwin.
Mueser, K. T., Drake, R. E. and Wallach, M. A. (1998). Dual diagnosis: a review of etiological theories. Addictive Behaviors, 23, 717–734.
Muller, D., Roeder, F. and Orthner, H. (1973). Further results of stereotaxis in the human hypothalamus in sexual deviations. First use of this operation in addiction to drugs. Neurochirurgia, 16, 113–126.
Müller, U. J., Sturm, V., Voges, J., et al. (2009). Successful treatment of chronic resistant alcoholism by deep brain stimulation of nucleus accumbens: first experience with three cases. Pharmacopsychiatry, 42, 288–291.
Munafò, M. R. (2009). The clinical utility of genetic tests. Addiction, 104, 127–128.
Munafò, M. R., Clark, T. and Flint, J. (2005a). Promise and pitfalls in the meta-analysis of genetic association studies: a response to Sen and Schinka. Molecular Psychiatry, 10, 895–897.
Munafò, M. R., Matheson, I. J. and Flint, J. (2007). Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias. Molecular Psychiatry, 12, 454–461.
Munafò, M. R., Shields, A. E., Berrettini, W. H., et al. (2005b). Pharmacogenetics and nicotine addiction treatment. Pharmacogenomics, 6, 211–223.
Munro, C. A., Saxton, J. and Butters, M. A. (2000). The neuropsychological consequences of abstinence among older alcoholics: a cross-sectional study. Alcoholism, Clinical and Experimental Research, 24, 1510–1516.
Murphy, M. R., Checkley, S. A., Seckl, J. R., et al. (1990). Naloxone inhibits oxytocin release at orgasm in man. Journal of Clinical Endocrinology and Metabolism, 71, 1056–1058.
Murray, C. J. L. and Lopez, A. D. (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: World Health Organization.
Murray, T. (2004). Ethical issues in immunotherapies or depot medications for substance abuse. In H. J. Harwood and T. G. Myers (Eds.), New Treatments for Addiction: Behavioral, Ethical Legal and Social Questions (pp. 188–212). Washington DC: National Academies Press.
Myrick, H. and Anton, R. (2004). Recent advances in the pharmacotherapy of alcoholism. Current Psychiatry Reports, 6, 332–338.
Nace, E., Birkmayer, F., Sullivan, M., et al. (2007). Socially sanctioned coercion mechanisms for addiction treatment. American Journal on Addictions, 16, 15–23.
Naqvi, N. H., Rudrauf, D., Damasio, H., et al. (2007). Damage to the insula disrupts addiction to cigarette smoking. Science, 315, 531–534.
National Advisory Council on Alcohol Abuse and Alcoholism. (1989). Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.
National Advisory Council on Drug Abuse. (2005). NACDA Guidelines for Administration of Drugs to Human Subjects. Rockville, MD: National Institute on Drug Abuse.
National Bioethics Advisory Commission. (1999). Research Involving Persons with Mental Disorders that may Affect Decision-making Capacity. Rockville, MD: National Bioethics Advisory Commission.
National Health and Medical Research Council. (1999). National Statement on Ethical Conduct in Research Involving Humans. Canberra: National Health and Medical Research Council, Commonwealth of Australia.
National Institute on Drug Abuse. (2010). A double-blind, randomized, placebo-controlled, multi-center study to assess the clinical efficacy, safety, and immunogenicity of a human cocaine vaccine (TA-CD) in the treatment of cocaine dependence. Available at: (Accessed 6 October 2010.)
National Research Council. (2001). Informing America's Policy on Illegal Drugs: What We Don't Know Keeps Hurting Us. Washington, DC: National Academy Press.
Neale, J. (2002). Drug Users in Society. New York: Palgrave.
Nelkin, D. (1973). Methadone Maintenance: A Technological Fix. New York: G. Braziller.
Nelkin, D. and Lindee, M. S. (1996). “Genes made me do it”: the appeal of biological explanations. Politics and the Life Sciences, 15, 95–97.
Nestler, E. J. (2000). Genes and addiction. Nature Genetics, 26, 277–281.
Nestler, E. J. (2004). Molecular mechanisms of drug addiction. Neuropharmacology, 47 Supplement 1, 24–32.
Newman, M. and Berris, J. (1941). Artificial hibernation therapy. Archives of Physiological Therapy, 22, 161–167.
Newman, R. (1974). Involuntary treatment of drug addiction. In P. G. Bourne (Ed.), Addiction (pp. 113–126). New York: Academic Press.
NIAAA. (2000). 10th Special Report to the US Congress on Alcohol and Health Highlights from the Current Research. Bethseda: National Institute on Alcohol Abuse and Alcoholism.
Nisell, M., Nomikos, G. G. and Svensson, T. H. (1994). Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse, 16, 36–44.
Noddings, N. (1984). Caring: A Feminine Approach to Ethics and Moral Education. Berkeley: University of California Press.
Numa, R., Kohen, R., Poltyrev, T., et al. (2008). Tempol diminishes cocaine-induced oxidative damage and attenuates the development and expression of behavioral sensitization. Neuroscience, 155, 649–658.
Nussbaum, M. (1990). Love's Knowledge: Essays on Philosophy and Literature. New York: Oxford University Press.
Nutt, D. (1996). Addiction: brain mechanisms and their treatment implications. Lancet, 347, 31–36.
Nutt, D. (2003). Death and dependence: current controversies over the selective serotonin reuptake inhibitors. Journal of Psychopharmacology, 17, 355–364.
Nutt, D. (2006). Alcohol alternatives – a goal for psychopharmacology?Journal of Psychopharmacology, 20, 318–320.
Nutt, D., King, L. A., Saulsbury, W., et al. (2007a). Development of a rational scale to assess the harm of drugs of potential misuse. Lancet, 369, 1047–1053.
Nutt, D. and Lingford-Hughes, A. (2004). Infecting the brain to stop addiction?Proceedings of the National Academy of Sciences of the United States of America, 101, 11193–11194.
Nutt, D. and Lingford-Hughes, A. (2008). Addiction: the clinical interface. British Journal of Pharmacology, 154, 397–405.
Nutt, D., Robbins, T. and Stimson, G. (2007c). Drugs futures 2025. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 1–6). London: Academic Press.
Nutt, D., Robbins, T., Stimson, G., et al. (2007b). Drugs and the Future: Brain Science, Addiction and Society. London: Academic Press.
O'Brien, C. P. (2005). Anticraving medications for relapse prevention: a possible new class of psychoactive medications. American Journal of Psychiatry, 162, 1423–1431.
O'Brien, C. P. (2008). Prospects for a genomic approach to the treatment of alcoholism. Archives of General Psychiatry, 65, 132–133.
O'Brien, C. P., Childress, A. R., Ehrman, R., et al. (1998). Conditioning factors in drug abuse: can they explain compulsion?Journal of Psychopharmacology, 12, 15–22.
O'Brien, C. P. and Cornish, J. W. (2006). Naltrexone for probationers and parolees. Journal of Substance Abuse Treatment, 31, 107–111.
O'Brien, C. P., Volkow, N. and Li, T. K. (2006). What's in a word? Addiction versus dependence in DSM-V. American Journal of Psychiatry, 163, 764–765.
O'Connell, T. J. and Bou-Matar, C. B. (2007). Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduction Journal, 4, 16–22.
O'Connor, P. G. and Kosten, T. R. (1998). Rapid and ultrarapid opioid detoxification techniques. JAMA, 279, 229–234.
Olds, J. and Milner, P. (1954). Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. Journal of Comparative and Physiological Psychology, 47, 419–427.
ONDCP. (2004). The Economic Costs of Drug Abuse in the United States. Washington, DC: Office of National Drug Control Policy.
Orellana, C. (2002). Controversy over brain surgery for heroin addiction in Russia. Lancet Neurology, 1, 333.
Oreskes, N. and Conway, E. M. (2010). Merchants of Doubt: How a Handful of Scientists Obscured the Truth on Issues from Tobacco Smoke to Global Warming. New York: Bloomsbury Press.
Orford, J. (2011). An Unsafe Bet: The Dangerous Rise of Gambling and the Debate We Should be Having. Chichester: John Wiley and Sons.
Orson, F. M., Kinsey, B. M., Singh, R. A. K., et al. (2008). Substance abuse vaccines. Annals of the New York Academy of Sciences, 1141, 257–269.
Outram, S. M. (2010). The use of methylphenidate among students: the future of enhancement?Journal of Medical Ethics, 36, 198–202.
Pacula, R. L., Chriqui, J. F., Reichmann, D. A., et al. (2002). State medical marijuana laws: understanding the laws and their limitations. Journal of Public Health Policy, 23, 413–439.
Pani, P. P., Trogu, E., Vacca, R., et al. (2010). Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews, CD007024.
Papp, M., Klimek, V. and Willner, P. (1994). Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology, 115, 441–446.
Parens, E. (2002). How far will the treatment/enhancement distinction get us as we grapple with new ways to shape ourselves? In S. J. Marcus (Ed.), Neuroethics: Mapping the Field (pp. 152–158). New York: Dana Press.
Parker, L. A. and Siegel, S. (2001). Modulation of the effects of rewarding drugs by ibogaine. In G. Cordell (Ed.), The Alkaloids: Chemistry and Biology (Vol. 56, pp. 211–225): Academic Press.
Pascual-Leone, A., Davey, N., Wassermann, E. M., et al. (2002). Handbook of Transcranial Magnetic Stimulation. New York: Oxford University Press.
Passetti, F., Clark, L., Mehta, M. A., et al. (2008). Neuropsychological predictors of clinical outcome in opiate addiction. Drug and Alcohol Dependence, 94, 82–91.
Paulus, M. P. (2007). Decision-making dysfunctions in psychiatry altered homeostatic processing?Science, 318, 602–606.
Paulus, M. P., Tapert, S. F. and Schuckit, M. A. (2005). Neural activation patterns of methamphetamine-dependent subjects during decision making predict relapse. Archives of General Psychiatry, 62, 761–768.
Pedic, F. (1990). Drug Use in Prisons: Data Collection Procedures. A Review and Recommendations. Sydney: National Drug and Alcohol Research Centre, University of New South Wales.
Peele, S. (1998). The Meaning of Addiction: An Unconventional View. San Francisco, CA: Jossey-Bass Publishers.
Peele, S. (2004). The surprising truth about addiction. Psychology Today, 37, 43.
Perneger, T. V., Giner, F., del Rio, M., et al. (1998). Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. British Medical Journal, 317, 13–18.
Persson, I. and Savulescu, J. (2011). Unfit for the future? Human nature, scientific progress and the need for moral enhancement. In J. Savulscu, R. ter Meulen and G. Kahane (Eds.), Enhancing Human Capacities (pp. 486–500). Oxford: Wiley-Blackwell.
Pescosolido, B. A., Martin, J. K., Long, J. S., et al. (2010). “A disease like any other?”: a decade of change in public reactions to schizophrenia, depression, and alcohol dependence. American Journal of Psychiatry, 167, 1321–1330.
Peto, J. (2001). Cancer epidemiology in the last century and the next decade. Nature, 411, 390–395.
Petry, N. M. (2006). Should the scope of addictive behaviors be broadened to include pathological gambling?Addiction, 101 Suppl 1, 152–160.
Pettinati, H. M., O'Brien, C. P., Rabinowitz, A. R., et al. (2006). The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. Journal of Clinical Psychopharmacology, 26, 610–625.
Pierce, J. P., Gilpin, E. A., Emery, S. L., et al. (1998). Has the California tobacco control program reduced smoking?JAMA, 280, 893.
Pilla, M., Perachon, S., Sautel, F., et al. (1999). Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature, 400, 371–375.
Pitman, R. K., Sanders, K. M., Zusman, R. M., et al. (2002). Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biological Psychiatry, 51, 189–192.
Platt, J. J., Buhringer, G., Kaplan, C. D., et al. (1988). The prospects and limitations of compulsory treatment for drug addiction. Journal of Drug Issues, 18, 505–525.
Pollock, J. D. and Ramaswami, M. (2009). The genetics and epigenetics of addiction. Journal of Neurogenetics, 23(3), 251.
Pontius, A. (1973). Neuro-ethics of “walking” in the newborn. Perceptual and Motor Skills, 37, 129–145.
Porrino, L. J., Daunais, J. B., Rogers, G. A., et al. (2005). Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biology, 3, 1639–1652.
Porter, L., Arif, A. and Curran, W. J. (1986). The Law and the Treatment of Drug- and Alcohol-Dependent Persons: A Comparative Study of Existing Legislation. Geneva: WHO.
Potenza, M. N. (2006). Should addictive disorders include non-substance-related conditions?Addiction, 101 Suppl 1, 142–151.
Potenza, M. N. (2008). The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philosophical Transactions of the Royal Society B-Biological Sciences, 363, 3181–3189.
Potter, V. R. (1970). Bioethics, the science of survival. Perspectives in Biology and Medicine, 14, 127–153.
Presenza, L. J. (2006). Naltrexone as a “mandate” or as a choice: comments on “Judicially mandated naltrexone use by criminal offenders: a legal analysis”. Journal of Substance Abuse Treatment, 31, 129–130.
Press, N. (2006). Social construction and medicalization: behavioral genetics in context. In E. Parens, A. R. Chapman and N. Press (Eds.), Wrestling with Behavioral Genetics: Science, Ethics and Public Conversation (pp. 131–149). Baltimore: Johns Hopkins University Press.
Preti, A. (2007). New developments in the pharmacotherapy of cocaine abuse. Addiction Biology, 12, 133–151.
Pritchard, E., Mugavin, J. and Swan, A. (2007). Compulsory Treatment in Australia: A Discussion Paper on the Compulsory Treatment of Individuals Dependent on Drugs and/or Alcohol. Canberra: Australian National Council on Drugs.
Productivity Commission. (2010). Gambling, Report no. 50. Canberra: Australian Government.
Rabin, R. L. and Sugarman, S. D. (Eds.). (2001). Regulating Tobacco. Oxford: Oxford University Press.
Rachels, J. (1999). The Elements of Moral Philosophy. Boston: McGraw-Hill.
Racine, E. (2003). Discourse ethics as an ethics of responsibility: comparison and evaluation of citizen involvement in population genomics. Journal of Law, Medicine and Ethics, 31, 390–397.
Racine, E. (2008). Which naturalism for bioethics? A defense of moderate (pragmatic) naturalism. Bioethics, 22, 92–100.
Racine, E. (2010). Pragmatic Neuroethics: Improving Treatment and Understanding of the Mind-brain. Cambridge: MIT Press.
Racine, E., Bar-Ilan, O. and Illes, J. (2005). fMRI in the public eye. Nature Reviews. Neuroscience, 6, 159–164.
Racine, E., Bar-Ilan, O. and Illes, J. (2006). Brain imaging: a decade of coverage in the print media. Science Communication, 28, 122–142.
Racine, E., van der Loos, H. Z. and Illes, J. (2007). Internet marketing of neuroproducts: new practices and healthcare policy challenges. Cambridge Quarterly of Healthcare Ethics, 16, 181–194.
Ragan, I. (2007). Drugs futures 2025? Perspectives of the pharmaceutical industry. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 507–532). London: Academic Press.
Rapeli, P., Kivisaari, R., Autti, T., et al. (2006). Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry, 6, 9.
Rasmussen, N. (2008). On Speed: The Many Lives of Amphetamine. New York: New York University Press.
Rassool, G. H. (2007). Some considerations on attitudes to addictions: waiting for the tide to change. Journal of Addictions Nursing, 18, 61–63.
Rawls, J. (1971). A Theory of Justice. Cambridge, MA: Belknap Press of the Harvard University Press.
Rawson, R. A., McCann, M. J., Hasson, A. J., et al. (2000). Addiction pharmacotherapy 2000: new options, new challenges. Journal of Psychoactive Drugs, 32, 371–378.
Read, J. and Law, A. (1999). The relationship of causal beliefs and contact with users of mental health services to attitudes to the ‘mentally ill’. International Journal of Social Psychiatry, 45, 216.
Rehm, J., Room, R., van den Brink, W., et al. (2005). Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. European Neuropsychopharmacology, 15, 389–397.
Renthal, W. and Nestler, E. J. (2008). Epigenetic mechanisms in drug addiction. Trends in Molecular Medicine, 14, 341–350.
Resnik, D. B. (1998). The Ethics of Science: An Introduction. New York: Routledge.
Reverby, S. (2009). Examining Tuskegee: The Infamous Syphilis Study and its Legacy. Chapel Hill: University of North Carolina Press.
Reynolds, A. (1992, July). Interface between health and law. Winter School in the Sun (July). Brisbane: Alcohol and Drug Foundation of Queensland.
Rhee, S. H., Hewitt, J. K., Young, S. E., et al. (2003). Genetic and environmental influences on substance initiation, use, and problem use in adolescents. Archives of General Psychiatry, 60, 1256–1264.
Ridding, M. C. and Rothwell, J. C. (2007). Is there a future for therapeutic use of transcranial magnetic stimulation?Nature Reviews. Neuroscience, 8, 559–567.
Ridgely, M., Iguchi, M. and Chiesa, J. (2004). The use of immunotherapies and sustained-release formulations in the treatment of drug addiction: will current law support coercion? In H. J. Harwood and T. G. Myers (Eds.), New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions (pp. 173–187). Washington, DC: National Academies Press.
Risinger, R. C., Salmeron, B. J., Ross, T. J., et al. (2005). Neural correlates of high and craving during cocaine self-administration using BOLD fMRI. Neuroimage, 26, 1097–1108.
Robbins, T. W., Cardinal, R. N., DiCiano, P., et al. (2007). Neuroscience of drugs and addiction. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 11–88). London: Academic Press.
Robbins, T. W. and Everitt, B. J. (1999). Drug addiction: bad habits add up. Nature, 398, 567–570.
Robbins, T. W. and Everitt, B. J. (2002). Limbic-striatal memory systems and drug addiction. Neurobiology of Learning and Memory, 78, 625–636.
Roberts, L. W. (2002a). Addiction and consent. American Journal of Bioethics, 2, 58–60.
Roberts, L. W. (2002b). Informed consent and the capacity for voluntarism. American Journal of Psychiatry, 159, 705–712.
Roberts, L. W. and Dunn, L. B. (2003). Ethical considerations in caring for women with substance use disorders. Obstetrics and Gynecology Clinics of North America, 30, 559–582.
Robinson, S., Sandstrom, S. M., Denenberg, V. H., et al. (2005). Distinguishing whether dopamine regulates liking, wanting, and/or learning about rewards. Behavioral Neuroscience, 119, 5–15.
Robinson, T. E. and Berridge, K. C. (2000). The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction, 95 Suppl 2, S91–117.
Robinson, T. E. and Kolb, B. (2004). Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology, 47, 33–46.
Rogers, R. D., Everitt, B. J., Baldacchino, A., et al. (1999). Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology, 20, 322–339.
Rogers, R. D. and Robbins, T. W. (2001). Investigating the neurocognitive deficits associated with chronic drug misuse. Current Opinion in Neurobiology, 11, 250–257.
Rollema, H., Coe, J. W., Chambers, L. K., et al. (2007). Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends in Pharmacological Sciences, 28, 316–325.
Room, R. (2005). Stigma, social inequality and alcohol and drug use. Drug and Alcohol Review, 24, 143–155.
Room, R. (2006). Taking account of cultural and societal influences on substance use diagnoses and criteria. Addiction, 101 Suppl 1, 31–39.
Room, R. (2007). Social policy and psychoactive substances. In D. Nutt, T. Robbins, G. Stimson, et al. (Eds.), Drugs and the Future: Brain Science, Addiction and Society (pp. 337–358). London: Academic Press.
Room, R., Fischer, B., Hall, W., et al. (2010). Cannabis Policy: Moving Beyond Stalemate. Oxford: Oxford University Press.
Room, R., Greenfield, T. and Weisner, C. (1991). People who might have liked you to drink less: changing responses to drinking by US family members and friends. Contemporary Drug Problems, Winter, 573–595.
Roper, P. (1966). Drug addiction, psychotic illness and brain self-stimulation: effective treatment and explanatory hypothesis. Canadian Medical Association Journal, 95, 1080–1086.
Rosack, J. (2007). FDA panel recommends against depression-treatment device. Psychiatric News, 42, 2.
Rose, G. (1992). The Strategy of Preventive Medicine. Oxford: Oxford University Press.
Rose, N. (2003). The neurochemical self and its anomalies. In R. Ericson (Ed.), Risk and Morality (pp. 407–437). Toronto: University of Toronto Press.
Roskies, A. L. (2007). Neuroethics beyond genethics. Despite the overlap between the ethics of neuroscience and genetics, there are important areas where the two diverge. EMBO Reports, 8 Spec No, S52–56.
Ross, P. (2003). Mind readers. Scientific American, 289, 74–77.
Rotgers, F. (1992). Coercion in addictions treatment. In F. Rotgers, J. W. Langebucher, B. S. McCrady, et al. (Eds.), Annual Review of the Addictions Research and Treatment (pp. 403–416). New York: Pergamon Press.
Rothstein, M. A. (1998). Genetic privacy and confidentiality: why they are so hard to protect. Journal of Law Medicine & Ethics, 26, 198–204.
Rothstein, M. A. (2008). Putting the Genetic Information Non-discrimination Act in context. Genetics in Medicine, 10, 655.
Rothstein, M. A. and Anderlik, M. R. (2001). What is genetic discrimination, and when and how can it be prevented?Genetics in Medicine, 3, 354–358.
Rouaud, T., Lardeux, S., Panayotis, N., et al. (2010). Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proceedings of the National Academy of Sciences, 107, 1196–1200.
Safire, W. (2002). Visions for a new field of “neuroethics”. In S. J. Marcus (Ed.), Neuroethics: Mapping the Field. San Fransisco: The Dana Press.
Sahakian, B. J. and Morein-Zamir, S. (2007). Professor's little helper. Nature, 450, 1157–1159.
Salomon, L., Lanteri, C., Glowinski, J., et al. (2006). Behavioral sensitization to amphetamine results from an uncoupling between noradrenergic and serotonergic neurons. Proceedings of the National Academy of Sciences, 103, 7476–7481.
SAMSHA. (2006). Results from the 2005 National Survey on Drugs Use and Health: National Findings. Rockville, MD: Office of Applied Studies, Substance Abuse and Mental Health Services Administration.
Sani, S., Jobe, K., Smith, A., et al. (2007). Deep brain stimulation for treatment of obesity in rats. Journal of Neurosurgery, 107, 809–813.
Sarnyai, Z. (1998). Oxytocin and neuroadaptation to cocaine. Progress in Brain Research, 119, 449–466.
Sarnyai, Z. and Kovacs, G. L. (1994). Role of oxytocin in the neuroadaptation to drugs of abuse. Psychoneuroendocrinology, 19, 85–117.
Sartorius, N. (2010). Short-lived campaigns are not enough. Nature, 468, 163–165.
Satel, S. (1999). The fallacies of no-fault addiction. Public Interest, 52–67.
Satel, S. and Lilenfeld, S. (2007). Medical misnomer: addiction isn't a brain disease, Congress. Slate. Available at: (Accessed 2 August 2007.)
Savulescu, J. (2005). New breeds of humans: the moral obligation to enhance. Reproductive Biomedicine Online, 10 Suppl 1, 36–39.
Schaub, M., Stevens, A., Berto, D., et al. (2010). Comparing outcomes of ‘voluntary’and ‘quasi-compulsory’treatment of substance dependence in Europe. European Addiction Research, 16, 53–60.
Scherbaum, N., Klein, S., Kaube, H., et al. (1998). Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry, 31, 205–209.
Scherbaum, N. and Rist, F. (2010). Opiate addicts' attitudes towards heroin prescription. Open Addiction Journal, 3, 109–116.
Schiff, N. D., Giacino, J. T. and Fins, J. J. (2009). Deep brain stimulation, neuroethics, and the minimally conscious state: moving beyond proof of principle. Archives of Neurology, 66, 697–702.
Schlaepfer, T. E., Cohen, M. X., Frick, C., et al. (2008). Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology, 33, 368–377.
Schoenbaum, G., Roesch, M. R. and Stalnaker, T. A. (2006). Orbitofrontal cortex, decision-making and drug addiction. Trends in Neurosciences, 29, 116–124.
Schultz, W. (2006). Behavioral theories and the neurophysiology of reward. Annual Review of Psychology, 57, 87–115.
Schultz, W. (2007). Behavioral dopamine signals. Trends in Neurosciences, 30, 203–210.
Schultz, W. (2010). Dopamine signals for reward value and risk: basic and recent data. Behavioral and Brain Functions, 6, 24.
Schultz, W., Dayan, P. and Montague, P. R. (1997). A neural substrate of prediction and reward. Science, 275, 1593–1599.
Schumann, G. (2007). Okey Lecture 2006: identifying the neurobiological mechanisms of addictive behaviour. Addiction, 102, 1689–1695.
Schupbach, M., Gargiulo, M., Welter, M. L., et al. (2006). Neurosurgery in Parkinson disease: a distressed mind in a repaired body?Neurology, 66, 1811–1816.
Schutz, C. (2008). Using neuroimaging to predict relapse to smoking: role of possible moderators and mediators. International Journal of Methods in Psychiatric Research, 17, S78–S82.
Scott, C. K. and White, W. L. (2005). Ethical issues in the conduct of longitudinal studies of addiction treatment. Journal of Substance Abuse Treatment, 28, S91–S101.
See, R. E. (2005). Neural substrates of cocaine-cue associations that trigger relapse. European Journal of Psychopharmacology, 526, 140–146.
Servello, D., Porta, M., Sassi, M., et al. (2008). Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: the surgery and stimulation. Journal of Neurology, Neurosurgery & Psychiatry, 79, 136–142.
Sevy, S., Smith, G. S., Ma, Y., et al. (2008). Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology, 197, 549–556.
Shaham, Y. and Hope, B. T. (2005). The role of neuroadaptations in relapse to drug seeking. Nature Neuroscience, 8, 1437–1439.
Sharma, T. (1974). Abolition of opiate hunger in humans following bilateral anterior cingulotomy. Texas Medicine, 70, 49–52.
Sheldon, J. (1987). Legal and ethical issues in the behavioural treatment of juvenile and adult offenders. In E. Morris and C. Braukmann (Eds.), Behavioural Approaches to Crime and Delinquency. Sydney: NSW Drug and Alcohol Authority.
Sherman, W. (2006). Test targets addiction gene. New York Daily News. Available at: (Accessed 13 April 2011.)
Shorter, E. and Healy, D. (2007). Shock Therapy: A History of Electroconvulsive Therapy in Mental Illness. New Brunswick: Rutgers University Press.
Sigmon, S. C., Moody, D. E., Nuwayser, E. S., et al. (2006). An injection depot formulation of buprenorphine: extended biodelivery and effects. Addiction, 101, 420–432.
Singer, P. (1993). A Companion to Ethics. Oxford: Blackwell.
Singer, T., Kiebel, S. J., Winston, J. S., et al. (2004). Brain responses to the acquired moral status of faces. Neuron, 41, 653–662.
Singh, I. and Rose, N. (2009). Biomarkers in psychiatry. Nature, 460, 202–207.
Skene, L. (1987). An evaluation of a Victorian scheme for diversion of alcoholic and drug dependent offenders. Australian and New Zealand Journal of Criminology, 20, 247–268.
Slotema, C. W., Blom, J. D., Hoek, H. W., et al. (2010). Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. Journal of Clinical Psychiatry, 71, 873–884.
Small, W., Kain, S., Laliberte, N., et al. (2005). Incarceration, addiction and harm reduction: inmates' experience injecting drugs in prison. Substance Use & Misuse, 40, 831–843.
Smeding, H. M., Goudriaan, A. E., Foncke, E. M., et al. (2007). Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. Journal of Neurology, Neurosurgery & Psychiatry, 78, 517–519.
Smeding, H. M., Speelman, J. D., Koning-Haanstra, M., et al. (2006). Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology, 66, 1830–1836.
Smith, K. L., Horton, N. J., Saitz, R., et al. (2006). The use of the mini-mental state examination in recruitment for substance abuse research studies. Drug and Alcohol Dependence, 82, 231–237.
Smith, L., Watson, M., Gates, S., et al. (2008). Meta-analysis of the association of the Taq1A polymorphism with the risk of alcohol dependency: a HuGE gene-disease association review. American Journal of Epidemiology, 167, 125–138.
Sobel, B. F., Sigmon, S. C., Walsh, S. L., et al. (2004). Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug and Alcohol Dependence, 73, 11–22.
Sobell, L. C. (2007). The phenomenon of self-change: overview and key issues. In H. Klingemann and L. C. Sobell (Eds.), Promoting Self-Change From Addictive Behaviors (pp. 1–30). New York, NY: Springer.
Sofuoglu, M. and Kosten, T. R. (2006). Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opinion on Emerging Drugs, 11, 91–98.
Sowell, E. R., Thompson, P. M. and Toga, A. W. (2004). Mapping changes in the human cortex throughout the span of life. Neuroscientist, 10, 372–392.
Spooner, C., Hall, W. and Mattick, R. P. (2001a). An overview of diversion strategies for Australian drug-related offenders. Drug and Alcohol Review, 20, 281–294.
Spooner, C., Lynskey, M. and Hall, W. (2001b). Structural Determinants of Youth Drug Use. Canberra: Australian National Council on Drugs.
Spriggs, M. (2003). Can we help addicts become more autonomous? Inside the mind of an addict. Bioethics, 17, 542–554.
Spriggs, M. (2005). Autonomy and Patients' Decisions. Lanham, MD: Lexington Books.
Srisurapanont, M. and Jarusuraisin, N. (2005). Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 8, 267–280.
Stamford, J. A., Muscat, R., O'Connor, J. J., et al. (1991). Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine. Psychopharmacology, 105, 275–282.
Stapleton, J. A. (2009). Trial comes too late as psychiatric side effects end hope for rimonabant. Addiction, 104, 277–278.
Stathis, H. (1991). Drug Use Among Offenders: A Literature Review. Sydney: Research and Statistics Division, NSW Department of Corrective Services.
Stathis, H., Bertram, S. and Eyland, S. (1991). Patterns of Drug Use Amongst NSW Prison Receptions. NSW: Research and Statistics Division, NSW Department of Corrective Services.
Steensland, P., Simms, J. A., Holgate, J., et al. (2007). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America, 104, 12518–12523.
Stelten, B. M., Noblesse, L. H., Ackermans, L., et al. (2008). The neurosurgical treatment of addiction. Neurosurgical Focus, 25, E5.
Stevens, J. (1987). Storming Heaven: LSD and the American Dream. New York: William Heinemann.
Stitzer, M., Iguchi, M., Kidorf, M., et al. (1993). Contingency management in methadone treatment: the case for positive incentives. In L. Onken, J. Blaine and J. Boren (Eds.), Behavioral Treatments for Drug Abuse and Dependence (pp. 19–36). Rockville, MD: National Indicate of Drug Abuse.
Stock, G. (2002). Redesigning Humans: Choosing our Children's Genes. London: Profile Books.
Stratton, K., Shetty, P., Wallace, R. J., et al. (2001). Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: National Academy Press.
Sugarman, J., McCrory, D. C., Powell, D., et al. (1999). Empirical research on informed consent. An annotated bibliography. Hastings Center Report, 29, S1–42.
Sullivan, M., Birkmayer, F., Boyarsky, B., et al. (2008). Uses of coercion in addiction treatment: clinical aspects. American Journal on Addictions, 17, 36–47.
Swayze, V. W., 2nd. (1995). Frontal leukotomy and related psychosurgical procedures in the era before antipsychotics (1935–1954): a historical overview. American Journal of Psychiatry, 152, 505–515.
Synofzik, M. and Schlaepfer, T. E. (2008). Stimulating personality: ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnology Journal, 3, 1511–1520.
Synofzik, M. and Schlaepfer, T. E. (2011). Electrodes in the brain: ethical criteria for research and treatment with deep brain stimulation for neuropsychiatric disorders. Brain Stimulation, 4, 7–16.
Szasz, T. S. (1975). Ceremonial Chemistry: The Ritual Persecution of Drugs, Addicts, and Pushers. London: Routledge.
Tassin, J. -P. (2008). Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse. Biochemical Pharmacology, 75, 85–97.
Taylor, S. (1998). A case study of genetic discrimination: social work and advocacy within a new context. Australian Social Work, 51, 51–57.
Taylor, S., Treloar, S., Barlow-Stewart, K., et al. (2008). Investigating genetic discrimination in Australia: a large-scale survey of clinical genetics clients. Clinical Genetics, 74, 20–30.
Teesson, M., Hall, W. and Degenhardt, L. (2002). Addictions. Hove: Psychology Press.
Tercyak, K. P., Peshkin, B. N., Abraham, A., et al. (2007). Interest in genetic counseling and testing for adolescent nicotine addiction susceptibility among a sample of adolescent medicine providers attending a scientific conference on adolescent health. Journal of Adolescent Health, 41, 42–50.
Tercyak, K. P., Peshkin, B. N., Wine, L. A., et al. (2006). Interest of adolescents in genetic testing for nicotine addiction susceptibility. Preventive Medicine, 42, 60–65.
Thigpen, F., Thigpen, C. and Cleckley, H. (1953). Use of electric-convulsive therapy in morphine, meperidine, and related alkaloid addictions. Archives of Neurology and Psychiatry, 70, 452.
Thomas, M. J. and Buckmaster, L. (2007). ‘Naltrexone or methadone’? Debates about drug treatments for heroin dependence in the context of drugs policy. Parliamentary Library: Information, Analysis and Advice for the Parliament, 7, 1–21.
Thomasson, H. R., Edenberg, H. J., Crabb, D. W., et al. (1991). Alcohol and aldehyde dehydrogenase genotypes and alcoholism in Chinese men. American Journal of Human Genetics, 48, 677–681.
Tiffany, S. T. (1990). A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes. Psychological Review, 97, 147–168.
TILLIM, S. (1942). Opiate withdrawal treated with induced hypoglycemic reactions. American Journal of Psychiatry, 99, 84.
Time. (1939). Medicine: Keeley Cure. Time. Available at:,9171,761978,00.html (Accessed 12 April, 2011.)
Tracy, S. (2005). Alcoholism in America: From Reconstruction to Prohibition. Baltimore: Johns Hopkins University Press.
Trujillo, K. A. and Akil, H. (1991). Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 251, 85–87.
Trujillo, K. A. and Akil, H. (1995). Excitatory amino acids and drugs of abuse: a role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence. Drug and Alcohol Dependence, 38, 139–154.
Tsankova, N., Renthal, W., Kumar, A., et al. (2007). Epigenetic regulation in psychiatric disorders. Nature Reviews. Neuroscience, 8, 355–367.
Turner, S., Longshore, D., Wenzel, S., et al. (2002). A decade of drug treatment court research. Substance Use & Misuse, 37, 1489–1527.
Tyndale, R. F. (2003). Genetics of alcohol and tobacco use in humans. Annals of Medicine, 35, 94–121.
Udesky, L. (2010). The ethics of direct-to-consumer genetic testing. Lancet, 376, 1377–1378.
Uhl, G. R. and Grow, R. W. (2004). The burden of complex genetics in brain disorders. Archives of General Psychiatry, 61, 223–229.
Uhl, G. R., Li, M. D., Gelertner, J., et al. (2004). Molecular genetics of addiction vulnerability and treatment responses. Neuropsychopharmacology, 29, S26–S26.
UNAIDS. (2006). International Guidelines on HIV/AIDS and Human Rights (consolidated version). Available at: (Accessed 13 July, 2007.)
UNCHR. (1996). HIV/AIDS in Prisons. Statement by the Joint United Nations Programme on HIV/AIDS (Fifty-second session, item 8 of the Agenda). Strasbourg: United Nations Commission on Human Rights.
United Nations General Assembly. (1948). United Nations Declaration on Human Rights. Available at: (Accessed 14 June, 2011.)
UNODC. (2006a). HIV/AIDS and Custodial Settings in South East Asia: An Exploratory Review into the Issue of HIV/AIDS and Custodial Settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. Thailand: United Nations Office on Drugs and Crime.
UNODC. (2006b). HIV/AIDS Prevention, Care, Treatment and Support in Prison Settings: A Framework for an Effective National Response. Vienna: World Health Organization and the Joint United Nations Programme on HIV/AIDS.
UNODC. (2010). From Coercion to Cohesion: Treating Drug Dependence Through Healthcare, Not Punishment: Discussion Paper. Vienna: United Nations Office on Drugs and Crime.
UNODC and WHO. (2008). Principles of Drug Dependence Treatment. Vienna: United Nations Office on Drugs and Crime.
Urbanoski, K. A. (2010). Coerced addiction treatment: client perspectives and the implications of their neglect. Harm Reduction Journal, 7, 13.
Valenstein, E. S. (1973). Brain Control: A Critical Examination of Brain Stimulation and Psychosurgery. New York: Wiley.
Valenstein, E. S. (1986). Great and Desperate Cures: The Rise and Decline of Psychosurgery and Other Radical Treatments for Mental Illness. New York: Basic Books.
Valenstein, E. S. (1998). Blaming the Brain: The Truth About Drugs and Mental Health. New York: Free Press.
Van Hoyweghen, I. and Horstman, K. (2008). European practices of genetic information and insurance. JAMA, 300, 326.
Vassoler, F. M., Schmidt, H. D., Gerard, M. E., et al. (2008). Deep brain stimulation of the nucleus accumbens shell attenuates cocaine priming-induced reinstatement of drug seeking in rats. Journal of Neuroscience, 28, 8735–8739.
Vastag, B. (2002). Addiction treatment strives for legitimacy. JAMA, 288, 3096–3101.
Vastag, B. (2005). Addiction research. Ibogaine therapy: a ‘vast, uncontrolled experiment’. Science, 308, 345–346.
Vergne, D. E. and Anton, R. F. (2010). Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence. CNS and Neurological Disorders Drug Targets, 9, 50–54.
Verweij, M. (1999). Medicalization as a moral problem for preventive medicine. Bioethics, 13, 89–113.
Vineis, P., Schulte, P. and McMichael, A. J. (2001). Misconceptions about the use of genetic tests in populations. Lancet, 357, 709–712.
Visser-Vandewalle, V., Ackermans, L., van der Linden, C., et al. (2006). Deep brain stimulation in Gilles de la Tourette's syndrome. Neurosurgery, 58, E590.
Vlahov, D., Wang, C. L., Galai, N., et al. (2004). Mortality risk among new onset injection drug users. Addiction, 99, 946–954.
Vocci, F. and Chiang, C. N. (2001). Vaccines against nicotine: how effective are they likely to be in preventing smoking?CNS Drugs, 15, 505–514.
Vocci, F. and Ling, W. (2005). Medications development: successes and challenges. Pharmacology & Therapeutics, 108, 94–108.
Volkow, N. D., Chang, L., Wang, G. J., et al. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry, 158, 377–382.
Volkow, N. D. and Fowler, J. S. (2000). Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cerebral Cortex, 10, 318–325.
Volkow, N. D., Fowler, J. S. and Wang, G. J. (2003). The addicted human brain: insights from imaging studies. Journal of Clinical Investigation, 111, 1444–1451.
Volkow, N. D., Fowler, J. S. and Wang, G. J. (2004a). The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology, 47, 3–13.
Volkow, N. D., Fowler, J. S., Wang, G. J., et al. (2009). Imaging dopamine's role in drug abuse and addiction. Neuropharmacology, 56 Suppl 1, 3–8.
Volkow, N. D., Fowler, J. S., Wang, G. J., et al. (2004b). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular Psychiatry, 9, 557–569.
Volkow, N. D., Fowler, J. S., Wang, G. J., et al. (2007). Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Archives of Neurology, 64, 1575–1579.
Volkow, N. D., Fowler, J. S., Wolf, A. P., et al. (1991). Changes in brain glucose metabolism in cocaine dependence and withdrawal. American Journal of Psychiatry, 148, 621–626.
Volkow, N. D. and Li, T. -K. (2005). Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacology & Therapeutics, 108, 3–17.
Volkow, N. D. and Li, T. K. (2004). Drug addiction: the neurobiology of behaviour gone awry. Nature Reviews. Neuroscience, 5, 963–970.
Volkow, N. D. and O'Brien, C. P. (2007). Issues for DSM-V: should obesity be included as a brain disorder?American Journal of Psychiatry, 164, 708–710.
Volkow, N. D. and Wise, R. A. (2005). How can drug addiction help us understand obesity. Nature Neuroscience, 8, 555–560.
Volpicelli, J. R., Clay, K. L., Watson, N. T., et al. (1995). Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Journal of Clinical Psychiatry, 56 Suppl 7, 39–44.
Vorel, S. R., Ashby, C. R., Jr., Paul, M., et al. (2002). Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. Journal of Neuroscience, 22, 9595–9603.
Vos, T., Carter, R., Barendregt, J., et al. (2010). Assessing Cost-effectiveness in Prevention: ACE–prevention September 2010 Final Report. Brisbane: The University of Queensland.
Vosburg, S. K., Hart, C. L., Haney, M., et al. (2010). Modafinil does not serve as a reinforcer in cocaine abusers. Drug and Alcohol Dependence, 106, 233–236.
Vrecko, S. (2008). Capital ventures into biology: biosocial dynamics in the industry and science of gambling. Economy and Society, 37, 50–67.
Vrecko, S. (2010). Birth of a brain disease: science, the state and addiction neuropolitics. History of the Human Sciences, 23, 52–67.
Walker, R., Logan, T. K., Clark, J. J., et al. (2005). Informed consent to undergo treatment for substance abuse: a recommended approach. Journal of Substance Abuse Treatment, 29, 241–251.
Walker, T. (2008). Giving addicts their drug of choice: the problem of consent. Bioethics, 22, 314–320.
Wallace, A. L. (2004). Epidemiological and Economic Modelling of the Potential Impact of a Nicotine Vaccine on Smoking Cessation and Related Mortality and Morbidity in the Australian Population [Ph.D. Thesis]. Brisbane: School of Population Health, The University of Queensland.
Walsh, N. P. (2002). Russia bans brain surgery on drug addicts. The Guardian. Available at:,771816,00.html (Accessed 11 February 2007.)
Ward, J., Mattick, R. P. and Hall, W. (1992). Key Issues in Methadone Maintenance Treatment. Kensington, NSW: New South Wales University Press.
Ward, J., Mattick, R. P. and Hall, W. (1998a). Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Sydney: Harwood Academic Press.
Ward, J., Mattick, R. P. and Hall, W. (1998b). The use of urinalysis during opioid replacement therapy. In J. Ward, R. P. Mattick and W. Hall (Eds.), Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Sydney: Harwood Academic Press.
Wark, P. (2009). Naltrexone: can a pill cure alcoholism? The Sunday Times. Available at: (Accessed 4 October, 2010.)
Watkins, E. S. (2010). Technophilia and the pharmaceutical fix. Lancet, 376, 1638–1639.
Weisberg, D. S., Keil, F. C., Goodstein, J., et al. (2008). The seductive allure of neuroscience explanations. Journal of Cognitive Neuroscience, 20, 470–477.
Weisner, C. (1990). Coercion in alcohol treatment. In Institute of Medicine (Ed.), Broadening the Base of Treatment for Alcohol Problems (pp. 579–610). Washington, DC: National Academy Press.
Weiss, F., Maldonado-Vlaar, C. S., Parsons, L. H., et al. (2000). Control of cocaine-seeking behavior by drug-associated stimuli in rats: effects on recovery of extinguished operant-responding and extracellular dopamine levels in amygdala and nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America, 97, 4321–4326.
Welton, N. J., Johnstone, E. C., David, S. P., et al. (2008). A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine & Tobacco Research, 10, 231.
Wesson, D. R. and Ling, W. (2003). The clinical opiate withdrawal scale (COWS). Journal of Psychoactive Drugs, 35, 253–259.
West, R. (2006). Theory of Addiction. Carlton, Victoria: Blackwell Publishing.
Wexler, D. (1993). Therapeutic jurisprudence and changing conceptions of legal scholarship. Behavioural Science and the Law, 11, 17–29.
Whalen, P. J., Rauch, S. L., Etcoff, N. L., et al. (1998). Masked presentations of emotional facial expressions modulate amygdala activity without explicit knowledge. Journal of Neuroscience, 18, 411–418.
White, J., Bell, J., Saunders, J. B., et al. (2009). Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug and Alcohol Dependence, 103, 37–43.
White, N. (1996). Addictive drugs as reinforcers: multiple partial actions on memory systems. Addiction, 91, 921–949.
White, V., Hill, D., Siahpush, M., et al. (2003). How has the prevalence of cigarette smoking changed among Australian adults? Trends in smoking prevalence between 1980 and 2001. Tobacco Control, 12, ii67.
White, W. L. (1998). Slaying the Dragon: The History of Addiction Treatment and Recovery in America. Bloomington, IL.: Chestnut Health Systems/Lighthouse Institute.
White, W. L. (2003). The history of ‘medicinal specifics’ as addiction cures in the United States. Addiction, 98, 261–267.
WHO. (1993). The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization.
WHO. (1995). European Charter on Alcohol. Copenhagen: World Health Organization Regional Office for Europe.
WHO. (2004a). Developing the Ethical Review Process. Geneva: World Health Organization.
WHO. (2004b). Neuroscience of Psychoactive Substance Use and Dependence. Geneva: World Health Organization.
WHO. (2005). Basic Principles for Treatment and Psychosocial Support of Drug Dependent People Living with HIV/AIDS. Geneva: World Health Organization.
WHO. (2006). HIV/AIDS Treatment and Care for Injecting Drug Users: Clinical Protocol for the WHO European Region. Copenhagen: World Health Organization Regional Office for Europe.
WHO. (2008). Guidelines for the Psychosocially-assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization.
WHO. (2009). Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: An application of selected human rights principles. Available at: (Accessed 5 July, 2009.)
Wild, T. C. (1999). Compulsory substance-user treatment and harm reduction: a critical analysis. Substance Use & Misuse, 34, 83–102.
Wild, T. C. (2006). Social control and coercion in addiction treatment: towards evidence-based policy and practice. Addiction, 101, 40–49.
Wild, T. C., Newton-Taylor, B. and Alletto, R. (1998). Perceived coercion among clients entering substance abuse treatment: structural and psychological determinants. Addictive Behaviors, 23, 81–95.
Wilfond, B., Geller, G., Lerman, C., et al. (2002). Ethical issues in conducting behavioral genetics research: the case of smoking prevention trials among adolescents. Journal of Health Care Law and Policy, 6, 73.
Willett, W. C. (2002). Balancing life-style and genomics research for disease prevention. Science, 296, 695–698.
Williams, J., Pacula, R. L., Chaloupka IV, F. J., et al. (2001). Alcohol and Marijuana Use Among College Students: Economic Complements or Substitutes?Cambridge, MA: National Bureau of Economic Research.
Williams, T. M., Daglish, M. R., Lingford-Hughes, A., et al. (2007). Brain opioid receptor binding in early abstinence from opioid dependence: positron emission tomography study. British Journal of Psychiatry, 191, 63–69.
Willner, P. (1997). The mesolimbic dopamine system as a target for rapid antidepressant action. International Clinical Psychopharmacology, 12 Suppl 3, S7–14.
Willner, P., Hale, A. S. and Argyropoulos, S. (2005). Dopaminergic mechanism of antidepressant action in depressed patients. Journal of Affective Disorders, 86, 37–45.
Wilson, D. B., Mitchell, O. and MacKenzie, D. L. (2006). A systematic review of drug court effects on recidivism. Journal of Experimental Criminology, 2, 459–487.
Wind, J. J. and Anderson, D. E. (2008). From prefrontal leukotomy to deep brain stimulation: the historical transformation of psychosurgery and the emergence of neuroethics. Neurosurgical Focus, 25, E10.
Wise, R. A. (1996). Neurobiology of addiction. Current Opinion in Neurobiology, 6, 243–251.
Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews. Neuroscience, 5, 483–494.
Wise, R. A. and Bozarth, M. A. (1987). A psychomotor stimulant theory of addiction. Psychological Review, 94, 469–492.
Wishart, H. A., Roberts, D. W., Roth, R. M., et al. (2003). Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: review and case reports. Journal of Neurology, Neurosurgery and Psychiatry, 74, 1392–1397.
Witjas, T., Baunez, C., Henry, J. M., et al. (2005). Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Movement Disorders, 20, 1052–1055.
Wodak, A. D., Ali, R., Henry, D., et al. (2008). Ensuring the safety of new medications and devices: are naltrexone implants safe?Medical Journal of Australia, 188, 438–439.
Wolf, M. E. (1998). The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Progress in Neurobiology, 54, 679–720.
Wolfe, D. (2007). Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. International Journal of Drug Policy, 18, 246–254.
Wolfe, D., Carrieri, M. and Shepard, D. (2010). Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet, 376, 355–366.
Wolpe, P. R. (2002). Treatment, enhancement, and the ethics of neurotherapeutics. Brain and Cognition, 50, 387–395.
Wood, E., Montaner, J. and Kerr, T. (2005). HIV risks in incarcerated injection-drug users. Lancet, 366, 1834–1835.
Wood, M. D. and Sher, K. J. (2000). Risks of alcohol consumption in laboratory studies involving human research participants. Psychology of Addictive Behaviors, 14, 328–334.
Wright, A. J., Aveyard, P., Guo, B., et al. (2007). Is attributing smoking to genetic causes associated with a reduced probability of quit attempt success? A cohort study. Addiction, 102, 1657–1664.
Wright, A. J., Weinman, J. and Marteau, T. M. (2003). The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tobacco Control, 12, 227–230.
Wu, H.-M., Wang, X.-L., Chang, C.-W., et al. (2010). Preliminary findings in ablating the nucleus accumbens using stereotactic surgery for alleviating psychological dependence on alcohol. Neuroscience Letters, 473, 77–81.
Xinhua News Agency. (2005). Brain surgery not resuming for curing drug addicts: health ministry. Xinhua News Agency, 16 April.
Xu, Z., Hou, B., Gao, Y., et al. (2007). Effects of enriched environment on morphine-induced reward in mice. Experimental Neurology, 204, 714–719.
Yahyavi-Firouz-Abadi, N. and See, R. E. (2009). Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacology & Therapeutics, 124, 235–247.
Yamamoto, T., Kobayashi, K., Kasai, M., et al. (2005). DBS therapy for the vegetative state and minimally conscious state. Acta Neurochirurgica. Supplement, 93, 101–104.
Yeomans, M. R. and Gray, R. W. (2002). Opioid peptides and the control of human ingestive behaviour. Neuroscience and Biobehavioral Reviews, 26, 713–728.
Yucel, M. and Lubman, D. I. (2007). Neurocognitive and neuroimaging evidence of behavioural dysregulation in human drug addiction: implications for diagnosis, treatment and prevention. Drug and Alcohol Review, 26, 33–39.
Zubieta, J., Gorelick, D. A., Stauffer, R., et al. (1996). Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Medicine, 2, 1225–1229.
Zubieta, J., Greenwald, M. K., Lombardi, U., et al. (2000). Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study. Neuropsychopharmacology, 23, 326–334.
Zullino, D. F., Krenz, S., Zimmerman, G., et al. (2005). Topiramate in opiate withdrawal – comparison with clonidine and with carbamazepine/mianserin. Substance Abuse, 25, 27–33.